WO2013167495A1 - Bicyclisch-substituierte uracile und ihre verwendung - Google Patents

Bicyclisch-substituierte uracile und ihre verwendung Download PDF

Info

Publication number
WO2013167495A1
WO2013167495A1 PCT/EP2013/059286 EP2013059286W WO2013167495A1 WO 2013167495 A1 WO2013167495 A1 WO 2013167495A1 EP 2013059286 W EP2013059286 W EP 2013059286W WO 2013167495 A1 WO2013167495 A1 WO 2013167495A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
alkyl
mmol
trifluoromethyl
methyl
Prior art date
Application number
PCT/EP2013/059286
Other languages
German (de)
English (en)
French (fr)
Inventor
Chantal FÜRSTNER
Jens Ackerstaff
Alexander Straub
Heinrich Meier
Hanna Tinel
Katja Zimmermann
Adrian Tersteegen
Dimitry Zubov
Raimund Kast
Jens Schamberger
Martina SCHÄFER
Kirsten BÖRNGEN
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA201413167A priority Critical patent/UA112897C2/uk
Priority to AP2014008096A priority patent/AP2014008096A0/xx
Priority to DK13720407.9T priority patent/DK2847190T3/en
Priority to JP2015510754A priority patent/JP6141414B2/ja
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Priority to AU2013258223A priority patent/AU2013258223B2/en
Priority to MYPI2014703273A priority patent/MY181828A/en
Priority to ES13720407.9T priority patent/ES2581537T3/es
Priority to EA201492040A priority patent/EA030383B9/ru
Priority to MX2018008811A priority patent/MX367599B/es
Priority to NZ701700A priority patent/NZ701700A/en
Priority to EP13720407.9A priority patent/EP2847190B1/de
Priority to CN201380034776.9A priority patent/CN104395310B/zh
Priority to BR112014028086-0A priority patent/BR112014028086B1/pt
Priority to RS20160510A priority patent/RS54901B1/sr
Priority to SI201330233A priority patent/SI2847190T1/sl
Priority to US14/399,945 priority patent/US9481672B2/en
Priority to MX2014013571A priority patent/MX357712B/es
Priority to CA2872906A priority patent/CA2872906C/en
Priority to KR1020147034155A priority patent/KR102083281B1/ko
Publication of WO2013167495A1 publication Critical patent/WO2013167495A1/de
Priority to IL235438A priority patent/IL235438A/en
Priority to CU2014000129A priority patent/CU20140129A7/es
Priority to ZA2014/08146A priority patent/ZA201408146B/en
Priority to PH12014502496A priority patent/PH12014502496A1/en
Priority to TN2014000470A priority patent/TN2014000470A1/fr
Priority to CR20140513A priority patent/CR20140513A/es
Priority to HK15103474.2A priority patent/HK1202873A1/xx
Priority to CY20161100636T priority patent/CY1118900T1/el
Priority to HRP20160796TT priority patent/HRP20160796T1/hr
Priority to US15/288,982 priority patent/US9949978B2/en
Priority to US15/288,968 priority patent/US9949977B2/en
Priority to IL253950A priority patent/IL253950B/en
Priority to AU2017265047A priority patent/AU2017265047B2/en
Priority to US15/912,185 priority patent/US10300062B2/en
Priority to US16/373,487 priority patent/US20200061063A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present application relates to novel bicyclic-substituted uracil derivatives, processes for their preparation, their use alone or in combinations for the treatment and / or prophylaxis of diseases and their use for the preparation of medicaments for the treatment and / or prophylaxis of diseases.
  • Chymase is a chymotrypsin-like serine protease that is stored as a macromolecular complex with heparin proteoglycans in secretory vesicles of mast cells. After activation of the mast cells, chymase is released into the extracellular matrix and activated.
  • mast cells play an important role in wound healing and inflammatory processes, e.g. Fibrosis of wounds, angiogenesis and cardiac remodeling (Miyazaki et al., Pharmacol Ther 112 (2006), 668-676; Shiota et al., J. Hypertens 21 (2003), 1823-1825).
  • An increase in the number of mast cells has been observed in heart failure, myocardial infarction and ischemia, in human atherosclerotic plaques and in the abdominal aortic aneurysm (Kovanen et al., Circulation 92 (1995), 1084-1088, Libby and Shi, Circulation 115 (2007), 2555) Bacani and Frishman, Cardiol. Rev.
  • Chymase-positive mast cells may also play an important role in respiratory vascular remodeling in asthma and chronic obstructive pulmonary disease. An increased number of mast cells has been found in endobronchial biopsies of asthma patients (Zanini et al., J. Allergy Clin Immunol 120 (2007), 329-333). Moreover, chymase is suspected of contributing to the development of many renal diseases, such as diabetic nephropathy and polycystic kidney disease (Huang et al., J. Am. Soc. Nephrol. 14 (7) (2003), 1738-1747; McPherson et al., J. Am. Soc. Nephrol. 15 (2) (2004), 493-500).
  • Chymase is predominantly involved in the production of angiotensin II in the heart, in the arterial wall and in the lungs, whereas the angiotensin converting enzyme is responsible for the formation of the peptide in the circulatory system (Fleming L, Circ.Res 98 (2006) , 887-896).
  • chymase cleaves a number of other substrates of pathological importance. Chymase degrades extracellular matrix proteins, such as fibronectin, procollagen, and vitronectin, and tears off focal adhesions. It causes activation and release of TGF ⁇ from its latent form, which plays an important role in the development of cardiac hypertrophy and cardiac fibrosis.
  • the enzyme acts athero- genic by breaking down apolipoproteins and preventing the absorption of cholesterol by HDL.
  • the action of chymase leads to release and activation of the cytokine interleukin 1 with its pro-inflammatory properties. In addition, it contributes to the production of endothelin 1 (Bacani and Frishman, Cardiol. Rev. 14 (4) (2006), 187-193).
  • An accumulation of chymase-positive mast cells has been found in biopsies from patients with atopic dermatitis, Crohn's disease, chronic hepatitis and cirrhosis, and idiopathic interstitial pneumonia (Dogreil S.A., Expert Opin. Ther. Patents 18 (2008), 485-499).
  • chymase inhibitors for the treatment of various diseases has been demonstrated in numerous animal studies. Inhibition of chymase may be useful for the treatment of myocardial infarction. Jin et al. ⁇ Pharmacol. Exp. Ther. 309 (2004), 409-417) showed that a ligation of the coronary artery in the dog to ventricular arrhythmias and increased production of angiotensin II and chymase activity in the heart. Intravenous administration of the chymase inhibitor TY-501076 reduced plasma chymase activity and angiotensin II concentration and suppressed the occurrence of arrhythmias.
  • Inhibition of chymase thus represents an effective principle in the treatment of cardiovascular diseases, inflammatory and allergic as well as different fibrotic diseases.
  • WO 2007/150011 and WO 2009/049112 disclose a process for the preparation of pyrimidine triones having glycine substituents.
  • WO 2008/056257 describes triazinediones as GABA-B receptor modulators for the treatment of CNS diseases.
  • WO 2008/103277 discloses various nitrogen heterocycles for the treatment of cancer.
  • WO 2009/156182 describes uracil derivatives for the suppression or reduction of resistance formation in the treatment of cytostatics.
  • the object of the present invention was to provide novel substances which act as inhibitors of chymase and are suitable as such for the treatment and / or prophylaxis of diseases, in particular cardiovascular diseases.
  • the present invention relates to compounds of the general formula (I)
  • A is -CH 2 - or oxygen
  • n is a number 0, 1 or 2
  • R 4 is halogen, difluoromethyl, trifluoromethyl, (C 1 -C 4) -alkyl, difluoromethoxy, trifluoromethoxy or (C 1 -C 4) -alkoxy,
  • R 5A is hydrogen or deuterium
  • R 5B is hydrogen, deuterium or (C 1 -C 4) -alkyl
  • R 6 is hydrogen or fluorine
  • R 7 is hydrogen or fluorine
  • R 8 is halogen, difluoromethyl, trifluoromethyl, (C 1 -C 4) -alkyl or nitro,
  • R 9 represents hydrogen, halogen, difluoromethyl, trifluoromethyl, (C 1 -C 4) -alkyl, nitro or (C 1 -C 4) -
  • the ring Q is 5- to 7-membered heterocyclyl or 5- or 6-membered heteroaryl
  • R 24 is halogen, (C 1 -C 4 ) -alkyl or (C 1 -C 4 ) -alkoxy,
  • n stands for a number 0, 1, 2 or 3
  • the present invention relates to compounds of the general formula (I)
  • R 1 is hydrogen or (C 1 -C 4 ) -alkyl
  • A is -CH 2 -, -CH 2 -CH 2 -, -O-CH 2 - ## or oxygen
  • n is a number 0, 1 or 2
  • R 4 is halogen, difluoromethyl, trifluoromethyl, (C 1 -C 4 -alkyl, difluoromethoxy, trifluoromethoxy or (C 1 -C 4 -alkoxy),
  • R 5A is hydrogen or deuterium
  • R 5B is hydrogen, deuterium or (OC-alkyl
  • R 6 is hydrogen or fluorine
  • R 7 is hydrogen or fluorine
  • R 8 is halogen, difluoromethyl, trifluoromethyl, (C 1 -C 4 -alkyl or nitro,
  • R 9 represents hydrogen, halogen, difluoromethyl, trifluoromethyl, (C 1 -C 4 -alkyl, nitro or (C 1 -C 4) -
  • the ring Q is 5- to 7-membered heterocyclyl or 5- or 6-membered heteroaryl, wherein 5- to 7-membered heterocyclyl and 5- or 6-membered heteroaryl having 1 to 4 substituents independently of the group halogen, difluoromethyl, trifluoromethyl, trideuteromethyl, (Ci-C 6 ) alkyl, (C 3 - C 7 ) -cycloalkyl, oxo, hydroxy, (C 1 -C 4 ) -alkylcarbonyl, (C 1 -C 4 ) -alkoxycarbonyl, aminocarbonyl and (C 1 -C 4 -alkylsulfonyl may be substituted, wherein (C 1 -C 6) -alkyl and (C3 -C7) -cycloalkyl may in turn be substituted by 1 to 3 substituents independently of one another selected from the group consisting of halogen, cyano, trifluoromethyl, (C
  • R 24 is halogen, (C 1 -C 4 ) -alkyl or (C 1 -C 4 ) -alkoxy,
  • n stands for a number 0, 1, 2 or 3
  • Compounds according to the invention are the compounds of the formula (I) and their salts, solvates and solvates of the salts comprising the compounds of the formulas below and their salts, solvates and solvates of the salts and of the formula (I) encompassed by formula (I), hereinafter referred to as exemplary compounds and their salts, solvates and solvates of the salts, as far as the compounds of formula (I), the compounds mentioned below are not already salts, solvates and solvates of the salts.
  • Salts used in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. Also included are salts which are not suitable for pharmaceutical applications themselves, but can be used, for example, for the isolation, purification or storage of the compounds according to the invention.
  • Physiologically acceptable salts of the compounds of the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, ethanesulfonic, toluenesulfonic, benzenesulfonic, naphthalenedisulfonic, acetic, trifluoroacetic, propionic, lactic, tartaric, malic, citric, fumaric, maleic and benzoic acids.
  • Salts of hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, ethanesulfonic, toluenesulfonic, benzenesulfonic, naphthalenedisulfonic acetic, trifluoroacetic, propionic, lactic, tartaric, malic, citric, fumaric, maleic and benzoic acids.
  • Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, as examples and preferably ethylamine, diethylamine, triethylamine, N, N-Düso- propylethylamine, monoethanolamine, diethanolamine, trisethanolamine, dimethylaminoethanol, diethylaminoethanol, procaine, dicyclohexylamine, dibenzylamine, iV-methylpiperidine, Af-methylmorpholine, arginine, lysine, choline and 1,2-ethylenediamine.
  • customary bases such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alka
  • Solvates in the context of the invention are those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates that coordinate with water. As solvates, hydrates are preferred in the context of the present invention.
  • the compounds according to the invention may exist in different stereoisomeric forms, ie in the form of configurational isomers or optionally also as conformational isomers (enantiomers and / or diastereomers, including those in the case of atropisomers).
  • the present invention therefore includes the enantiomers and diastereomers and their respective mixtures.
  • the stereoisomerically uniform components can be isolated in a known manner; Preferably, chromatographic methods are used for this, in particular HPLC chromatography on achiral or chiral phase.
  • the present invention encompasses all tautomeric forms.
  • the present invention also encompasses all suitable isotopic variants of the compounds according to the invention.
  • An isotopic variant of a compound according to the invention is understood to mean a compound in which at least one atom within the compound according to the invention is exchanged for another atom of the same atomic number but with a different atomic mass than the atomic mass that usually or predominantly occurs in nature.
  • isotopes that can be incorporated into a compound of the invention are those of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, such as 2 H (deuterium), ⁇ (tritium), 13 C , 14 C, 15 N, 17 0, 18 0, 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 C, 82 Br, 123 I, 124 I, 129 I, and 131 I.
  • isotopic variants of a compound of the invention such as, in particular, those in which one or more radioactive isotopes are incorporated, may be useful, for example, for the study of the mechanism of action or distribution of active ingredient in the body; Due to the comparatively easy production and detectability, compounds labeled with 3 H or 14 C isotopes in particular are suitable for this purpose.
  • the incorporation of isotopes such as deuterium may result in certain therapeutic benefits as a result of greater metabolic stability of the compound, such as prolonging the body's half-life or reducing the required effective dose; Such modifications of the compounds of the invention may therefore optionally also constitute a preferred embodiment of the present invention.
  • Isotopic variants of the compounds according to the invention can be prepared by the processes known to the person skilled in the art, for example by the methods described below and the rules given in the exemplary embodiments, by using appropriate isotopic modifications of the respective reagents and / or starting compounds.
  • the present invention also includes prodrugs of the compounds of the invention.
  • prodrugs here denotes compounds which themselves may be biologically active or inactive, but be converted during their residence time in the body on, for example, metabolic or hydrolytic routes to compounds of the invention.
  • alkyl is a linear or branched alkyl radical having in each case the number of carbon atoms specified. Examples which may be mentioned are: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 1-methylpropyl, tert-butyl, n-pentyl, isopentyl, 1-ethylpropyl, 1-methylbutyl , 2-methylbutyl, 3-methylbutyl, n -hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,4-dimethylpentyl , 4,4-dimethylpentyl and 1, 4,4-trimethylpentyl.
  • Cycloalkyl in the context of the invention is a monocyclic, saturated alkyl radical having 3 to 7 carbon atoms. Examples which may be mentioned by way of example include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Alkylcarbonyl in the context of the invention is a linear or branched alkyl radical having 1 to 4 carbon atoms and a carbonyl group attached in the 1-position.
  • alkylcarbonyl in the context of the invention is a linear or branched alkyl radical having 1 to 4 carbon atoms and a carbonyl group attached in the 1-position.
  • Alkoxy in the context of the invention represents a linear or branched alkoxy radical of 1 to 4 carbon atoms. Examples which may be mentioned by way of example include: methoxy, ethoxy, w-propoxy, isopropoxy, w-butoxy and tert. Butoxy.
  • Alkoxycarbonyl in the context of the invention are a linear or branched alkoxy radical having 1 to 4 carbon atoms and an oxygen-bonded carbonyl group.
  • Alkylthio in the context of the invention is a linear or branched alkyl radical having 1 to 4 carbon atoms which is bonded via a sulfur atom.
  • Alkylsulfonyl in the context of the invention is a linear or branched alkyl radical having 1 to 4 carbon atoms, which is bonded via a sulfonyl group.
  • a sulfonyl group By way of example and preferably its name: methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, iso-propylsulfonyl, n-butylsulfonyl and tert-butylsulfonyl.
  • 4- to 7-membered heterocyclyl in the context of the invention represents a monocyclic, saturated heterocycle having a total of 4 to 7 ring atoms, which contains one or two ring heteroatoms from the series N, O, S, SO and / or SO 2 and via a ring carbon atom or optionally a ring nitrogen atom. is knotted. Examples which may be mentioned are: azetidinyl, oxetanyl, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl.
  • 5- to 7-membered heterocyclyl is in the context of the invention for a partially unsaturated heterocycle having a total of 5 to 7 ring atoms containing 1 to 3 ring heteroatoms from the series N, O, S and / or SO 2 and to the phenyl ring in R 3 is annealed.
  • Examples which may be mentioned are: dihydropyrrolyl, dihydroimidazolyl, dihydrothiazole dioxide, dihydrooxazolyl, dihydropyridyl, tetrahydropyrazinyl and dihydrooxazinyl.
  • Heteroaryl is in the context of the invention for a monocyclic aromatic heterocycle (Heteroaro- maten) with a total of 5 or 6 ring atoms containing up to three identical or different ring heteroatoms from the series N, O and / or S and to the phenyl ring in R 3 is annealed.
  • Heteroaro- maten monocyclic aromatic heterocycle with a total of 5 or 6 ring atoms containing up to three identical or different ring heteroatoms from the series N, O and / or S and to the phenyl ring in R 3 is annealed.
  • Examples which may be mentioned are: furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and triazinyl.
  • furyl pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and triazinyl.
  • pyrazolyl imidazolyl, thiazolyl and triazolyl.
  • Halogen in the context of the invention includes fluorine, chlorine, bromine and iodine. Preference is given to chlorine or fluorine.
  • An oxo group in the context of the invention represents an oxygen atom which is bonded via a double bond to a carbon or sulfur atom.
  • radicals are substituted in the compounds according to the invention, the radicals can, unless otherwise specified, be monosubstituted or polysubstituted. In the context of the present invention, the meaning is independent of each other for all radicals which occur repeatedly. Substitution with one or two identical or different substituents is preferred. Very particular preference is given to the substitution with a substituent.
  • treatment includes inhibiting, delaying, arresting, alleviating, attenuating, restraining, reducing, suppressing, restraining or curing a disease, a disease, a disease, an injury or a medical condition , the unfolding, the course or progression of such conditions and / or the symptoms of such conditions.
  • therapy is understood to be synonymous with the term “treatment”.
  • prevention means the avoidance or reduction of the risk, a disease, a disease, a disease, an injury or a health disorder, a development or a Progression of such conditions and / or to get, experience, suffer or have the symptoms of such conditions.
  • the treatment or the prevention of a disease, a disease, a disease, an injury or a health disorder can be partial or complete.
  • R 1 is hydrogen, methyl or ethyl
  • R 2 is a group of the formula
  • A is -CH 2 - or oxygen
  • R 4A is hydrogen, fluorine, chlorine, trifluoromethyl or methyl
  • R 4B is hydrogen, fluorine, chlorine, trifluoromethyl or methyl
  • R 4A and R 4B are other than hydrogen ' R 5A is hydrogen
  • R 5B is hydrogen
  • R 6 is hydrogen
  • R 7 is hydrogen
  • R 8 is fluorine, chlorine, difluoromethyl, trifluoromethyl or methyl
  • R 9 is fluorine, chlorine, difluoromethyl, trifluoromethyl or methyl
  • R 3 is a group of the formula
  • E 1 is CR 11 or N
  • R 11 is hydrogen, (C 1 -C 4 ) -alkyl, (C 3 -C 7) -cycloalkyl or aminocarbonyl,
  • E 2 is CR 12 or N
  • R 12 is hydrogen, (C 1 -C 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
  • E 3 is NR 14 or S
  • R 14 is hydrogen, (C 1 -C 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
  • G 2 is CR 16A R 16B , NR 17 , O or S,
  • Ri6A ßj Is hydrogen, fluorine, (C 1 -C 4 ) -alkyl or hydroxyl,
  • R i is ffa is hydrogen, fluorine, chlorine, (C 1 -C 4 ) -alkyl or trifluoromethyl,
  • R 16A and R 16B together with the carbon atom to which they are attached form a 3- to 6-membered carbocycle
  • R 17 is hydrogen, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or (C 1 -C 4 ) -alkoxycarbonyl, wherein (C 1 -C 6 ) -alkyl having 1 to 3 substituents is independently selected from the group fluorine, trifluoromethyl, cyano, (C 3 -C 7 ) -cycloalkyl, hydroxy, trifluoromethoxy, (C 1 -C 4 ) -alkoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl may be substituted,
  • G 3 is CR 18A R 18B , NR 19 , O or S,
  • R 18A is hydrogen, fluorine, (C 1 -C 4 ) -alkyl or hydroxyl
  • RisB Is hydrogen, fluorine, chlorine, (C 1 -C 4) -alkyl or trifluoromethyl,
  • R 18A and R 18B together with the carbon atom to which they are attached form a 3- to 6-membered carbocycle
  • R 19 is hydrogen, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or (C 1 -C 4 ) -alkoxycarbonyl, wherein (C 1 -C 6 ) -alkyl having 1 to 3 substituents is selected independently of one another from the group fluorine, trifluoromethyl, cyano, (C 3 -C 7 ) -cycloalkyl, hydroxy, trifluoromethoxy, (C 1 -C 4 ) -alkoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl may be substituted,
  • K 1 is CH 2 or O
  • K 2 is CH 2 or O, with the proviso that only one of the groups K 1 and K 2 is O,
  • D 1 , D 2 , D 3 and D 4 independently of one another represent CR 23 or N,
  • R 23 is hydrogen, halogen, (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
  • R 24 is fluorine or methyl
  • n is a number 0 or 1
  • R 10 is (C 1 -C 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl
  • Oxetanyl, tetrahydrofuranyl and pyrrolidinyl may be substituted
  • R 13 is hydrogen, (C 1 -C 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
  • R 15 is hydrogen, (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
  • Oxetanyl, tetrahydrofuranyl and pyrrolidinyl may be substituted
  • R 20 is hydrogen, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or (C 1 -C 4 ) -alkylcarbonyl,
  • Oxetanyl, tetrahydrofuranyl and pyrrolidinyl may be substituted
  • R 21 is hydrogen, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or (C 1 -C 4 ) -alkylsulfonyl,
  • R22A ftjj Is hydrogen or (C 1 -C) -alkyl
  • R22B ⁇ is hydrogen or (Ci-C) -alkyl
  • R 22A and R 22B together with the carbon atom to which they are attached form carbonyl group, as well as their salts, solvates and solvates of the salts.
  • R 1 is hydrogen, methyl or ethyl
  • R 2 is a group of the formula
  • A is -CH 2 -, -CH 2 -CH 2 -, -O-CH 2 - ## or oxygen
  • R 4A is hydrogen, fluorine, chlorine, trifluoromethyl or methyl
  • R 4B is hydrogen, fluorine, chlorine, trifluoromethyl or methyl
  • R 4A and R 4B are other than hydrogen ' R 5A is hydrogen
  • R 5B is hydrogen
  • R 6 is hydrogen
  • R 7 is hydrogen
  • R 8 is fluorine, chlorine, difluoromethyl, trifluoromethyl or methyl
  • R 9 is fluorine, chlorine, difluoromethyl, trifluoromethyl or methyl
  • E 1 is CR 11 or N
  • R 11 is hydrogen, (C 1 -C 4 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or aniinocarbonyl,
  • E 2 is CR 12 or N
  • R 12 is hydrogen, (C 1 -C 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
  • E 3 is NR 14 or S
  • R 14 is hydrogen, (C 1 -C 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
  • G 2 is CR 16A R 16B , NR 17 , O or S, wherein
  • Ri6A ffa is hydrogen, fluorine, (C 1 -C 4 ) -alkyl or hydroxyl,
  • R i es ßj Is hydrogen, fluorine, chlorine, (C 1 -C 4 ) -alkyl or trifluoromethyl,
  • R 16A and R 16B together with the carbon atom to which they are attached form a 3- to 6-membered carbocycle
  • R 17 is hydrogen, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or (C 1 -C 4 ) -alkoxycarbonyl, wherein (C 1 -C 6 ) -alkyl having 1 to 3 substituents is independently selected from the group fluorine, trifluoromethyl, cyano, (C 3 -C 7 ) -cycloalkyl, hydroxy, trifluoromethoxy, (C 1 -C 4 ) -alkoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl may be substituted,
  • G 3 is CR 18A R 18B , NR 19 , O or S,
  • R 18A is hydrogen, fluorine, (C 1 -C 4 ) -alkyl or hydroxyl
  • RisB ffa is hydrogen, fluorine, chlorine, (C 1 -C 4 ) -alkyl or trifluoromethyl,
  • R 18A and R 18B together with the carbon atom to which they are attached form a 3- to 6-membered carbocycle
  • R 19 is hydrogen, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or (C 1 -C 4 ) -alkoxycarbonyl, wherein (C 1 -C 6 ) -alkyl having 1 to 3 substituents is selected independently of one another from the group fluorine, trifluoromethyl, cyano, (C 3 -C 7 ) -cycloalkyl, hydroxy, trifluoromethoxy, (C 1 -C 4 ) -alkoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl may be substituted,
  • K 1 is CH 2 or O
  • K 2 is CH 2 or O
  • D 1 , D 2 , D 3 and D 4 independently of one another represent CR 23 or N,
  • R 23 is hydrogen, halogen, (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
  • R 24 is fluorine or methyl
  • n is a number 0 or 1
  • R 10 is (C 1 -C 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl
  • Oxetanyl, tetrahydrofuranyl and pyrrolidinyl may be substituted
  • R 13 is hydrogen, (C 1 -C 4 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
  • R 15 is hydrogen, (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, in which (C 1 -C 6) -alkyl may be substituted by 1 or 2 substituents independently selected from the group consisting of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy, ethoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl,
  • R 20 is hydrogen, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or (C 1 -C 4 ) -alkylcarbonyl,
  • (C 1 -C 6) -alkyl may be substituted by 1 or 2 substituents independently selected from the group consisting of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy, ethoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl,
  • R 21 is hydrogen, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or (C 1 -C 4 ) -alkylsulfonyl,
  • R 22A ftjj Is hydrogen or (C 1 -C 4 ) -alkyl
  • R 22B ⁇ jj. Is hydrogen or (C 1 -C 4 ) -alkyl
  • R 22A and R 22B together with the carbon atom to which they are attached form a carbonyl group
  • R 2 is a group of the formula
  • A is -CH 2 -
  • R 4A is chlorine or trifluoromethyl
  • R 4B is hydrogen
  • E 1 stands for CR 11 , wherein
  • R 11 is hydrogen
  • G 2 is CR 16A R 16B , NR 17 , O or S,
  • R 16A is hydrogen, fluorine, methyl or hydroxy
  • R 16B is hydrogen, fluorine, methyl or trifluoromethyl
  • R 16A and R 16B together with the carbon atom to which they are attached form a cyclopropyl ring
  • R 17 is hydrogen, (C 1 -C 4 ) -alkyl or (C 3 -C 5 ) -cycloalkyl,
  • (C 1 -C 4) -alkyl may be substituted by 1 to 3 substituents independently selected from the group consisting of fluorine, trifluoromethyl, cyano, cyclopropyl, cyclobutyl, hydroxy, trifluoromethoxy, methoxy, ethoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl,
  • R 24 is hydrogen or fluorine
  • R 10 is (C 1 -C 4 ) -alkyl
  • R 15 is hydrogen, methyl or ethyl
  • methyl and ethyl may be substituted by 1 substituent selected from the group consisting of fluorine, trifluoromethyl and cyclopropyl,
  • R 1 is hydrogen
  • R 5A is hydrogen
  • R 5B is hydrogen
  • R 6 is hydrogen
  • R 7 is hydrogen
  • R 8 is fluorine, chlorine or trifluoromethyl
  • R 9 is fluorine, chlorine, trifluoromethyl or methyl
  • R 3 is a group of the formula
  • E 1 stands for CR 11 ,
  • R 11 is hydrogen
  • G 2 is CR 16A R 16B , NR 17 , O or S,
  • R 16A is hydrogen, fluorine, methyl or hydroxy
  • R 16B is hydrogen, fluorine, methyl or trifluoromethyl
  • R 16A and R 16B together with the carbon atom to which they are attached form a cyclopropyl ring
  • R 17 is hydrogen, (C 1 -C 4 ) -alkyl or (C 3 -C 5 ) -cycloalkyl,
  • R 24 is hydrogen or fluorine
  • R 10 is (C 1 -C 4 ) -alkyl
  • R 15 is hydrogen, methyl or ethyl
  • metyl and ethyl may be substituted with 1 substituent selected from the group fluorine, trifluoromethyl and cyclopropyl,
  • R 2 is a group of the formula
  • A is -CH 2 -
  • R 4A is chlorine or trifluoromethyl
  • R 4B is hydrogen
  • E 1 is CR 11 or N
  • R 11 is hydrogen, methyl, ethyl or aminocarbonyl
  • E 2 is CR 12 or N
  • R 12 is hydrogen
  • G 2 is CR 16A R 16B , NR 17 , O or S, wherein
  • R 16A is hydrogen, fluorine, methyl or hydroxy
  • R 16B is hydrogen, Huor, chlorine, methyl or trifluoromethyl
  • R 16A and R 16B together with the carbon atom to which they are attached form a cyclopropyl ring
  • R 17 is hydrogen, (C 1 -C 4) -alkyl, cyclopropyl or cyclobutyl,
  • (C 1 -C 4) -alkyl may be substituted by 1 or 2 substituents independently of one another selected from the group Hu, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, azetidinyl and oxetanyl,
  • R 18A is hydrogen, Huor, methyl or hydroxy
  • R 18B is hydrogen, Huor, methyl or trifluoromethyl
  • K 1 is CH 2 or 0
  • K 2 is CH 2 .
  • R 24 is hydrogen, fluorine or methyl
  • R 10 is methyl or ethyl
  • R 15 is methyl or ethyl
  • R 20 is hydrogen, methyl, ethyl or methylcarbonyl
  • R 21 is methyl or ethyl
  • R 22A and R 22B together with the carbon atom to which they are attached form a carbonyl group
  • A is -CH 2 -
  • R 4A is chlorine or trifluoromethyl
  • A is -CH 2 -
  • R 4A is hydrogen, fluorine, chlorine, trifluoromethyl or methyl
  • R 4B is hydrogen, fluorine, chlorine, trifluoromethyl or methyl
  • R 4A and R 4B are other than hydrogen
  • the carbon atom attached to the uracil nitrogen has an R configuration, and its salts, solvates and solvates of the salts.
  • Another object of the invention is a process for the preparation of compounds of the formula (I) according to the invention, characterized in that
  • R 1A is (C 1 -C 4 ) -alkyl
  • T 1 is (C 1 -C 4 ) -alkyl
  • T 2 is (C 1 -C 4 ) -alkyl
  • R 1A and R 3 each have the meanings given above
  • X 1 for hydroxy or a suitable leaving group in particular chlorine, bromine or iodine, is a compound of the formula (1-1)
  • R 1A and T 1 each have the abovementioned meanings
  • T 3 is (C 1 -C 4 ) -alkyl
  • R 1A and T 1 each have the meanings given above, and
  • T 5 is (C 1 -C 4 ) -alkyl
  • R 1A and R 2 each have the meanings given above
  • T 6 is hydrogen, (C 1 -C 4 ) -alkyl or both radicals T 6 together form a -C (CH 3 ) 2-C (CH 3 ) 2 -
  • R 1B is hydrogen
  • Inert solvents for process steps (II) + (III) (IV), (VI) + (III) (VII) and (VIII) + (IX) (X) are, for example, ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or Diethyleneglycol dimethyl ether, hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, trichlorethylene or chlorobenzene, alcohols such as methanol, ethanol, n-propanol, isopropanol or n-butanol, or other solvents such as dimethylformamide, dimethyl sulfoxide, ⁇ /, ⁇ / '- dimethylpropyleneurea (DMPU), A / -methylpyrroli
  • Suitable bases for process steps (II) + (III) -> (IV) and (VIII) + ( ⁇ ) -> (X) are alkali metal alkoxides such as sodium or potassium methoxide, sodium or potassium ethanolate or sodium or potassium tert-butylate, alkali metal hydrides such as sodium or potassium hydride, amides such as sodium amide, lithium or potassium bis (trimethylsilyl) amide or lithium diisopropylamide, or organic bases such as triethylamine, diisopropylethylamine, 1,5-diazabicyclo [4.3.0] non-5-ene (DBN), l, 8-diazabicyclo [5.4.0] undec-7-ene (DBU) or l, 4-diazabicyclo [2.2.2] - octane (DABCO ®), or phosphazene base such as l- [N-tert-butyl-P, P-di (pyrrolidin-1
  • the base is in this case generally used in an amount of 1 to 5 mol, preferably in an amount of 1.2 to 3 mol, based on 1 mol of the compound of formula (II) or (IX).
  • the reactions (II) + (III) - »(IV), (VI) + (III) -» (VII) and (VIII) + (IX) - »(X) are generally carried out in a temperature range of 0 ° C. to + 150 ° C, preferably at + 20 ° C to + 120 ° C, optionally in a microwave.
  • the reaction may be carried out at normal, elevated or reduced pressure (e.g., from 0.5 to 5 bar). Generally, one works at normal pressure.
  • reaction (IV) + (V) - »(1-1) takes place under Mitsunobu conditions [see: a) Hughes, DL” The Mitsunobu Reaction “Organic Reactions, John Wiley & Sons Ltd., 1992, vol. 42, p. 335. b) Hughes, DL Org., Prep., Proceed., Int, 1996, 28, 127].
  • the Mitsunobu reaction is carried out using triphenylphosphine, or tri-n-butylphosphine, 1,2-bis (diphenylphosphino) ethane (DPPE), diphenyl (2-pyridyl) phosphine (Ph 2 P-Py), (p-dimethylaminophenyl) diphenylphosphine (DAP-DP), tris (4-dimethylaminophenyl) phosphine (tris) DAP) and a suitable dialkyl azodicarboxylate such as diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), di-tert-butyl azodicarboxylate, ⁇ / NW tetramethyl azodicarboxamide (TMAD), 1,1'-azodicarbonyl-dipiperidine (ADDP) or 4,7-dimethyl-3,5,7-hexahydro-
  • Inert solvents for the Mitsunobu reaction (IV) + (V) - »(1-1) are, for example, ethers such as tetrahydrofuran, diethyl ether, hydrocarbons such as benzene, toluene, xylene, halogenated hydrocarbons such as dichloromethane, dichloroethane or other solvents such as Acetonitrile or dimethylformamide (DMF). It is likewise possible to use mixtures of the solvents mentioned. Preferably, THF or a mixture of THF and DMF is used.
  • the Mitsunobu reaction (IV) + (V) - »(1-1) is generally carried out in a temperature range from -78 ° C to + 180 ° C, preferably at 0 ° C to + 50 ° C, optionally in a microwave , The reactions may be carried out at normal, elevated or reduced pressure (e.g., from 0.5 to 5 bar).
  • reaction (IV) + (V) - »(1-1) takes place under conditions of nucleophilic substitution.
  • Inert solvents for process step (IV) + (V) - »(1-1) are then, for example, ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethyl-diglycol dimethyl ether, hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, Halogenated hydrocarbons such as dichloromethane, trichloromethane, 1, 2-dichloroethane, trichlorethylene or chlorobenzene, or other solvents such as dimethylformamide, dimethylsulfoxide, A ⁇ iV'-dimethylpropyleneurea (DMPU), iV-methylpyrrolidinone (NMP), pyrrolidinone (NMP), pyrroli
  • acetonitrile, DMF or acetonitrile is used in admixture with dimethylformamide.
  • base for the process step (IV) + (V) - »(1-1) are customary inorganic bases. These include in particular alkali metal or alkaline earth metal carbonates such as lithium, sodium, potassium, calcium or cesium carbonate, optionally with the addition of an alkali metal iodide such as potassium iodide, alkali metal alcoholates such as sodium or potassium, sodium or potassium or sodium or potassium tert.
  • alkali metal hydrides such as sodium or potassium hydride, amides such as sodium amide, lithium or potassium bis (trimethylsilyl) amide or lithium diisopropylamide.
  • Potassium carbonate is preferably used with potassium iodide or sodium hydride.
  • the base is in this case generally used in an amount of 1 to 5 mol, preferably in an amount of 1.2 to 3 mol, based on 1 mol of the compound of formula (IV).
  • the reaction (IV) + (V) - »(1-1) is generally carried out in a temperature range from 0 ° C to + 100 ° C, preferably at + 20 ° C to + 80 ° C, optionally in a microwave.
  • the reaction may be carried out at normal, elevated or reduced pressure (e.g., from 0.5 to 5 bar). Generally, one works at normal pressure.
  • Inert solvents for the process step (VII) - »(IV) are for example ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or other solvents such as Chlorobenzene, dimethylformamide, dimethyl sulfoxide, N, N'-dimethylpropyleneurea (DMPU), Af-methylpyrrolidinone (NMP), pyridine, acetone, 2-butanone or acetonitrile. It is likewise possible to use mixtures of the solvents mentioned. Preferably, toluene is used.
  • the reaction (VII) -> (IV) is generally carried out in a temperature range from 0 ° C to + 150 ° C, preferably at + 20 ° C to + 120 ° C, optionally in a microwave.
  • the reaction may be carried out at normal, elevated or reduced pressure (e.g., from 0.5 to 5 bar). Generally, one works at normal pressure.
  • Process step (X) + (XI) - »(1-1) is similar to a reaction referred to in the literature as Chan-Lam coupling.
  • Inert solvents for process step (X) + (XI) - »(1-1) are ethers, such as 1,4-dioxane or tetrahydrofuran, halogenated hydrocarbons, such as dichloromethane, trichloromethane, 1,2-dichloroethane, or other solvents, such as dimethylformamide ( DMF), N-methylpyrrolidone (NMP), acetonitrile or dimethyl sulfoxide (DMSO). It is likewise possible to use mixtures of the solvents mentioned.
  • DMF dimethylformamide
  • NMP N-methylpyrrolidone
  • DMSO dimethyl sulfoxide
  • Suitable bases for process step (X) + (XI) - »(1-1) are pyridine, pyridine derivatives such as. B. DMAP or organic tertiary amines such. For example, diisopropylethylamine or triethylamine.
  • Triethylamine is preferred if (XI) corresponds to a boronic ester or a trifluoroborate salt, or pyridine if (XI) is a boronic acid.
  • Suitable catalysts for process step (X) + (XI) -> (1-1) are copper (II) salts, such as, for example, copper (II) acetate or copper (II) triflate; copper (II )-Acetate.
  • the process step (X) + (XI) -> (1-1) is carried out in air or under an oxygen-containing atmosphere.
  • the reaction (X) + (XI) -> (1-1) is generally carried out in a temperature range of 0 ° C to + 150 ° C, preferably at + 20 ° C to + 80 ° C.
  • the hydrolysis of the ester group R 1A of the compound (1-1) to compounds of the formula (1-2) is carried out by treating the esters in inert solvents with acids or bases, wherein the latter salts by treatment with acid in the free carboxylic acids are transferred.
  • the ester hydrolysis is preferably carried out with acids.
  • Suitable inert solvents for these reactions are water, diethyl ether, tetrahydrofuran, dioxane or glycol dimethyl ether, or other solvents such as acetonitrile, acetic acid, dimethylformamide or dimethyl sulphoxide. It is likewise possible to use mixtures of the solvents mentioned. In the case of basic ester hydrolysis, preference is given to using mixtures of water with dioxane, tetrahydrofuran or acetonitrile.
  • Suitable bases are the alkali metal or alkaline earth metal hydrogen carbonates, such as sodium or potassium bicarbonate. Preference is given to sodium bicarbonate.
  • Suitable acids for the ester cleavage are generally sulfuric acid, hydrochloric acid / hydrochloric acid, hydrogen bromide / hydrobromic acid, phosphoric acid, acetic acid, trifluoroacetic acid, toluenesulfonic acid, methanesulfonic acid or trifluoromethanesulfonic acid or mixtures thereof, optionally with the addition of water.
  • Hydrogen chloride or trifluoroacetic acid in the case of the tert-butyl ester and hydrochloric acid in admixture with acetic acid, and sulfuric acid in admixture with acetic acid and water in the case of methyl esters and ethyl esters are preferred.
  • the ester cleavage is generally carried out in a temperature range from 0 ° C to 180 ° C, preferably at + 20 ° C to 120 ° C.
  • the reactions mentioned can be carried out at normal, elevated or reduced pressure (for example from 0.5 to 5 bar). In general, one works at normal pressure.
  • Other compounds of the invention may optionally also be prepared by conversions of functional groups of individual substituents, in particular the compounds listed under R 3 , starting from the compounds of formula (I) obtained by the above method.
  • These transformations are carried out as described in the present experimental part, according to customary methods known to the person skilled in the art, and include, for example, reactions such as nucleophilic and electrophilic substitutions, oxidations, reductions, hydrogenations, transition metal-catalyzed coupling reactions, eliminations, alkylation, amination, esterification, ester cleavage, Etherification, ether cleavage, formation of carbonamides, and introduction and removal of temporary protecting groups.
  • the conversion of functional groups can be exemplified by the following synthetic scheme (Scheme 4): Scheme 4:
  • the compounds according to the invention are inhibitors of chymase and are therefore suitable for the treatment and / or prophylaxis of cardiovascular, inflammatory, allergic and / or fibrotic disorders.
  • diseases of the cardiovascular system or cardiovascular diseases are to be understood as meaning, for example, the following diseases: acute and chronic heart failure, arterial hypertension, coronary heart disease, stable and unstable angina pectoris, myocardial ischemia, myocardial infarction, shock, atherosclerosis, Cardiac hypertrophy, cardiac fibrosis, atrial and ventricular arrhythmias, transient and ischemic attacks, stroke, preeclampsia, inflammatory cardiovascular diseases, peripheral and cardiac vascular diseases, peripheral circulatory disorders, arterial pulmonary hypertension, spasm of the coronary arteries and peripheral arteries, thrombosis, thromboembolic disorders, Edema formation such as pulmonary edema, cerebral edema, renal edema or heart failure-related edema, as well as reste
  • cardiac insufficiency also encompasses more specific or related forms of disease such as acute decompensated heart failure, right heart failure, left heart failure, global insufficiency, ischemic cardiomyopathy, dilated cardiomyopathy, congenital heart defects, valvular heart failure, cardiac valvulopathy, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, aortic valve insufficiency, tricuspid stenosis, Tricuspid regurgitation, pulmonary valve stenosis, pulmonary valvular insufficiency, combined valvular heart failure, myocarditis, chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, cardiac storage disorders, diastolic heart failure, and systolic heart failure.
  • ischemic cardiomyopathy dilated cardiomyopathy
  • congenital heart defects valvular heart failure
  • the compounds according to the invention are also suitable for the prophylaxis and / or treatment of polycystic kidney disease (PCKD) and of the syndrome of inadequate ADH secretion (SIADH).
  • PCKD polycystic kidney disease
  • SIADH syndrome of inadequate ADH secretion
  • the compounds according to the invention are suitable for the treatment and / or prophylaxis of kidney diseases, in particular of acute and chronic renal insufficiency, as well as of acute and chronic renal failure.
  • the term acute renal insufficiency includes acute manifestations of kidney disease, renal failure and / or renal insufficiency with and without the need for dialysis, such as also underlying or related renal diseases such as renal hypoperfusion, intradialytic hypotension, volume deficiency (eg dehydration, blood loss), shock, acute glomerulonephritis, hemolytic anemic syndrome (HUS), vascular catastrophic disease (arterial or venous thrombosis or embolism), cholesterol embolism, acute Bence Jones Kidney plasmocytoma, acute supravesical or subvesical drainage disorders, immunological kidney diseases such as kidney transplant rejection, immune complex-induced kidney disease, tubular dilation, hyperphosphatemia and / or acute kidney disease, which may be characterized by the need for dialysis, as well as partial kidney resection, dehydration by forced diuresis, uncontrolled increase in blood pressure with malignant hypertension, urinary obstruction and infection and amyloidosis as well as systemic diseases with
  • chronic renal insufficiency includes chronic manifestations of kidney disease, kidney failure and / or renal insufficiency with and without dialysis, as well as underlying or related renal diseases such as renal hypoperfusion, intradialytic hypotension, obstructive uropathy, glomerulopathies, glomerular and tubular Proteinuria, renal edema, hematuria, primary, secondary and chronic glomerulonephritis, membranous and membranoproliferative glomerulonephritis, Alport's syndrome, glomerulosclerosis, tubulointerstitial diseases, nephropathic disorders such as primary and congenital kidney disease, nephritis, immunological kidney diseases such as kidney transplant rejection, immune complex -induced kidney disease, diabetic and non-diabetic nephropathy, pyelonephritis, renal cysts, nephrosclerosis, hypertensive nephrosclerosis and ne
  • renal diseases such as renal hypoper
  • Glutamylsynthetase altered urinosmolarity or amount of urine, increased microalbuminuria, macroalbuminuria, lesions on glomeruli and arterioles, tubular dilatation, hyperphosphatemia and / or the need for dialysis can be characterized as well as renal cell carcinoma, after partial resections of the kidney, dehydration by forced diuresis, uncontrolled increase in blood pressure with malignant hypertension, urinary obstruction and infection and amyloidosis and systemic disorders with glomerular involvement, such as rheumatologic-immunological systemic disorders, such as lupus erythematosus, as well as renal artery stenosis, renal artery thrombosis, renal vein thrombosis, analgesic nephropathy and renal tubular acidosis.
  • the present invention also encompasses the use of the compounds according to the invention for the treatment and / or prophylaxis of sequelae of renal insufficiency, such as pulmonary edema, cardiac insufficiency, uremia, anemia, electrolyte disorders (eg hyperkalemia, hyponatremia) and disorders in the bone and carbohydrate. Metabolism.
  • sequelae of renal insufficiency such as pulmonary edema, cardiac insufficiency, uremia, anemia, electrolyte disorders (eg hyperkalemia, hyponatremia) and disorders in the bone and carbohydrate. Metabolism.
  • the compounds according to the invention are also suitable for the treatment and / or prophylaxis of pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH), the chronic obstructive pulmonary disease (COPD), acute respiratory tract syndrome (ARDS), acute lung injury (ALI), alpha-1-antrypsin deficiency (AATD), pulmonary fibrosis, pulmonary emphysema (eg, cigarette smoke-induced pulmonary emphysema), cystic fibrosis ( CF), acute coronary syndrome (ACS), heart muscle inflammation (myocarditis) and other autoimmune heart diseases (pericarditis, endocarditis, valvolitis, aortitis, cardiomyopathies), cardiogenic shock, aneurysms, sepsis (SIRS), multiple organ failure (MODS, MOF) , inflammatory diseases of the kidney, chronic intestinal inflammation (IBD, Crohn's Disease, UC), pancreatitis, peritonitis,
  • the compounds according to the invention can furthermore be used for the treatment and / or prophylaxis of asthmatic diseases of varying degrees of severity with intermittent or persistent course (refractive asthma, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, medications or dust-induced asthma), of various forms of bronchitis (chronic bronchitis, infectious bronchitis, eosinophilic bronchitis), bronchiolitis obliterans, bronchiectasis, pneumonia, idiopathic interstitial pneumonia, farmer's and related diseases, cough and cold diseases (chronic inflammatory cough, iatrogenic cough), nasal mucosal inflammation (including medicinal rhinitis, vasomotor rhinitis and season-dependent allergic rhinitis, eg hay fever) and polyps.
  • bronchitis chronic bronchitis, infectious bronchitis, eosinophilic bronchitis
  • the compounds according to the invention are suitable for the treatment and / or prophylaxis of fibrotic disorders of the internal organs, such as, for example, the lung, the heart, the kidney, the bone marrow and in particular the liver, as well as dermatological fibroses and fibrotic disorders of the eye.
  • fibrotic disorders includes in particular the following terms: liver fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, cardiomyopathy, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage as a consequence of diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, Hypertrophic scarring (also after surgical procedures), nevi, diabetic retinopathy and proliferative vitroretinopathy.
  • the compounds of the invention are useful for controlling postoperative scarring, e.g. as a result of glaucoma surgery.
  • the compounds according to the invention can also be used cosmetically on aging and keratinizing skin.
  • the compounds of the invention can also be used for the treatment and / or prophylaxis of dyslipidemias (hypercholesterolemia, hypertriglyceridemia, elevated levels of postprandial plasma triglycerides, hypoalphalipoproteinemia, combined hyperlipidemias), nephropathy and neuropathy), cancers (skin cancer, brain tumors, breast cancer, bone marrow tumors , Leukemia, liposarcoma, carcinomas of the gastrointestinal tract, liver, pancreas, lung, kidney, ureter, prostate and genital tract, as well as malignant tumors of the lymphoproliferative system such as Hodgkin's and Non-Hodgkin's Lymphoma), diseases of the gastrointestinal tract and the abdomen (Glossitis, gingivitis, periodontitis, esophagitis, eosinophilic gastroenteritis, mast
  • the compounds of the formula (I) according to the invention are furthermore suitable for the treatment and / or prophylaxis of ophthalmological diseases such as, for example, glaucoma, normotensive glaucoma, ocular hypertension and combinations thereof, age-related macular degeneration (AMD), dry or non-exudative AMD, moist or exudative or neovascular AMD , choroidal neovascularization (CNV), retinal detachment, diabetic retinopathy, atrophic retinal pigment epithelium (RPE), hypertrophic retinal pigment epithelium (RPE), diabetic macular edema, retinal vein occlusion, choroidal retinal vein occlusion, macular edema, macular edema due to retinal vein occlusion, angiogenesis at the front of the eye such as corneal angiogenesis for example after keratitis, cornea transplantation or keratoplasty, corneal angiogenesis due to hypoxia
  • Another object of the present invention is the use of the compounds of the invention for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is the use of the compounds of the invention for the manufacture of a medicament for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
  • the present invention furthermore relates to the compounds according to the invention for use in a method for the treatment and / or prophylaxis of cardiac insufficiency, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, renal insufficiency, nephropathies, fibrotic disorders of the internal organs and dermatological fibroses.
  • the compounds of the invention may be used alone or as needed in combination with other agents.
  • Another object of the present invention are therefore pharmaceutical compositions containing at least one of the compounds of the invention and one or more other active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
  • Suitable combination active substances which may be mentioned by way of example and by preference are:
  • the signal transduction cascade inhibiting compounds for example and preferably from the group of kinase inhibitors, in particular from the group of tyrosine kinase and / or serine / threonine kinase inhibitors;
  • MMPs matrix metalloproteases
  • stromelysin a matrix metalloproteases
  • collagenases a subset of cells
  • gelatinases a matrix metalloproteases
  • aggrecanases a subset of cells
  • MMP-12 metallo-elastase
  • organic nitrates and NO donors such as sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhaled NO;
  • NO-independent, but heme-dependent, stimulators of soluble guanylate cyclase in particular the compounds described in WO 00/06568, WO 00/06569, WO 02/42301 and WO 03/095451;
  • soluble guanylate cyclase in particular the compounds described in WO 01/19355, WO 01/19776, WO 01/19778, WO 01/19780, WO 02/070462 and WO 02/070510;
  • Prostacyclin analogs such as by way of example and preferably iloprost, beraprost, treprostinil or epoprostenol;
  • Compounds influencing the energy metabolism of the heart such as, for example and preferably, estimoxir, dichloroacetate, ranolazines or trimetazidines;
  • cGMP cyclic guanosine monophosphate
  • cAMP cyclic adenosine monophosphate
  • PDE phosphodiesterases
  • antithrombotic agents by way of example and preferably from the group of platelet aggregation inhibitors, anticoagulants or profibrinolytic substances;
  • antihypertensive agents by way of example and preferably from the group of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, vasopeptidase inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor B-relaxers, beta-receptor Bs , Mineralocorticoid receptor antagonists, Rho kinase inhibitors and diuretics;
  • Vasopressin receptor antagonists such as, and preferably, conivaptan, tolvaptan, lixivaptan, mozavaptan, satavaptan, SR-121463, RWJ 676070 or BAY 86-8050; bronchodilatory agents, for example and preferably from the group of beta-adrenergic receptor agonists, in particular albuterol, isoproterenol, metaproterenol, terbutaline, formoterol or salemoterol, or from the group of anticholinergics, in particular ipratropium bromide;
  • anti-inflammatory agents by way of example and with preference from the group of glucocorticoids, in particular prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, beclomethasone, betethasone, flunisolide, budesonide or fluticasone; and or
  • lipid metabolism-altering agents by way of example and preferably from the group of thyroid receptor agonists, cholesterol synthesis inhibitors such as by way of example and preferably HMG-CoA reductase or squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors, MTP inhibitors, PPAR alpha-alpha, PPAR gamma and / or PPAR delta agonists, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors, and lipoprotein (a) antagonists.
  • cholesterol synthesis inhibitors such as by way of example and preferably HMG-CoA reductase or squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors, MTP inhibitors, PPAR alpha-alpha, PPAR gamma and / or PPAR delta agonists, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile acid adsorbers, bile
  • the compounds according to the invention are used in combination with a kinase inhibitor, such as by way of example and preferably bortezomib, canertinib, erlotinib, fitinib, imatinib, lapatinib, lestaurtinib, lonafarnib, pegaptinib, pelitinib, semaxanib, sorafenib, regorafenib, Sunitinib, tandutinib, tipifarnib, vatalanib, fasudil, lonidamine, leflunomide, BMS-3354825 or Y-27632.
  • a kinase inhibitor such as by way of example and preferably bortezomib, canertinib, erlotinib, fitinib, imatinib, lapatinib, lestaurtinib, lonafarnib, pe
  • the compounds according to the invention are used in combination with a serotonin receptor antagonist, such as by way of example and preferably PRX-08066.
  • Antithrombotic agents are preferably understood as meaning compounds from the group of platelet aggregation inhibitors, anticoagulants or profibrinolytic substances.
  • the compounds according to the invention are administered in combination with a platelet aggregation inhibitor, such as, by way of example and by way of preference, aspirin, clopidogrel, ticlopidine or dipyridamole.
  • a platelet aggregation inhibitor such as, by way of example and by way of preference, aspirin, clopidogrel, ticlopidine or dipyridamole.
  • the compounds according to the invention are administered in combination with a thrombin inhibitor, such as, by way of example and by way of preference, ximelagatran, melagatran, bivalirudin or Clexane.
  • a thrombin inhibitor such as, by way of example and by way of preference, ximelagatran, melagatran, bivalirudin or Clexane.
  • the compounds according to the invention are administered in combination with a GPIIb / IIIa antagonist, such as, by way of example and by way of preference, tirofiban or abciximab.
  • a GPIIb / IIIa antagonist such as, by way of example and by way of preference, tirofiban or abciximab.
  • the compounds according to the invention are used in combination with a factor Xa inhibitor, such as by way of example and preferably rivaroxaban, DU-176b, fidexaban, razaxaban, fondaparinux, idraparinux, PMD-3112, YM-150, KFA-1982, EMD No.
  • the compounds according to the invention are administered in combination with heparin or a low molecular weight (LMW) heparin derivative.
  • LMW low molecular weight
  • the compounds according to the invention are administered in combination with a vitamin K antagonist, such as by way of example and preferably coumarin.
  • a vitamin K antagonist such as by way of example and preferably coumarin.
  • the antihypertensive agents are preferably compounds from the group of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha receptors B loose, beta receptors B loose, mineralocorticoid Receptor antagonists, Rho kinase inhibitors and diuretics understood.
  • the compounds according to the invention are administered in combination with a calcium antagonist, such as, by way of example and by way of preference, nifedipine, amlodipine, verapamil or diltiazem.
  • a calcium antagonist such as, by way of example and by way of preference, nifedipine, amlodipine, verapamil or diltiazem.
  • the compounds according to the invention are administered in combination with an alpha-1-receptor blocker, such as by way of example and preferably prazosin.
  • the compounds according to the invention are used in combination with a beta-receptor blocker such as, by way of example and by way of preference, propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol, bupranolol, metipranolol, nadolol, mepindolol, carazalol, Sotalol, metoprolol, betaxolol, celiprolol, bisoprolol, carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol, epanolol or bucindolol.
  • a beta-receptor blocker such as, by way of example and by way of preference, propranolol, atenolol
  • the compounds according to the invention are administered in combination with an angiotensin AII antagonist, such as by way of example and preferably losartan, candesartan, valsartan, telmisartan or embursatan.
  • an angiotensin AII antagonist such as by way of example and preferably losartan, candesartan, valsartan, telmisartan or embursatan.
  • the compounds according to the invention are administered in combination with an ACE inhibitor, such as by way of example and preferably enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
  • an ACE inhibitor such as by way of example and preferably enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
  • an endothelin antagonist such as, by way of example and by way of preference, bosentan, darusentan, ambristan or sitaxsentan.
  • the compounds of the invention are administered in combination with a renin inhibitor, such as by way of example and preferably aliskiren, SPP-600 or SPP-800.
  • a renin inhibitor such as by way of example and preferably aliskiren, SPP-600 or SPP-800.
  • the compounds according to the invention are administered in combination with a mineralocorticoid receptor antagonist, such as by way of example and preferably spironolactone or eplerenone.
  • the compounds according to the invention are used in combination with a rho-kinase inhibitor, such as, for example and preferably, Fasudil, Y-27632, SLx-2119, BF-66851, BF-66852, BF-66853, KI- 23095, SB-772077, GSK-269962A or BA-1049.
  • a rho-kinase inhibitor such as, for example and preferably, Fasudil, Y-27632, SLx-2119, BF-66851, BF-66852, BF-66853, KI- 23095, SB-772077, GSK-269962A or BA-1049.
  • the compounds according to the invention are administered in combination with a diuretic, such as by way of example and preferably furosemide.
  • lipid metabolizing agents are preferably compounds from the group of CETP inhibitors, thyroid receptor agonists, cholesterol synthesis inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors, ACAT inhibitors, MTP inhibitors, PPAR-alpha, PPAR gamma and / or PPAR delta agonists, cholesterol absorption inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors, lipase inhibitors and the lipoprotein (a) antagonists understood.
  • CETP inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors
  • ACAT inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors
  • MTP inhibitors MTP inhibitors
  • PPAR-alpha PPAR-alpha
  • PPAR gamma and / or PPAR delta agonists cholesterol absorption inhibitors
  • polymeric bile acid adsorbers bil
  • the compounds according to the invention are administered in combination with a CETP inhibitor, such as by way of example and preferably torcetrapib (CP-529 414), JJT-705 or CETP vaccine (Avant).
  • a CETP inhibitor such as by way of example and preferably torcetrapib (CP-529 414), JJT-705 or CETP vaccine (Avant).
  • the compounds of the invention are administered in combination with a thyroid receptor agonist such as, by way of example and by way of preference, D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214).
  • a thyroid receptor agonist such as, by way of example and by way of preference, D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214).
  • T3 3,5,3'-triiodothyronine
  • CGS 23425 CGS 23425
  • axitirome CGS 26214
  • the compounds according to the invention are administered in combination with an HMG-CoA reductase inhibitor from the class of statins, such as by way of example and preferably lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastat
  • the compounds according to the invention are administered in combination with a squalene synthesis inhibitor, for example and preferably BMS-188494 or TAK-475.
  • a squalene synthesis inhibitor for example and preferably BMS-188494 or TAK-475.
  • the compounds according to the invention are administered in combination with an ACAT inhibitor, such as by way of example and preferably avasimibe, melinamide, pactimibe, eflucimibe or SMP -797.
  • an ACAT inhibitor such as by way of example and preferably avasimibe, melinamide, pactimibe, eflucimibe or SMP -797.
  • the compounds according to the invention are administered in combination with an MTP inhibitor such as, for example and preferably, implitapide, BMS-201038, R-103757 or JTT-130.
  • the compounds according to the invention are administered in combination with a PPAR-gamma agonist, such as, by way of example and by way of preference, pioglitazone or rosiglita zone.
  • the compounds according to the invention are administered in combination with a PPAR delta agonist, such as by way of example and preferably GW 501516 or BAY 68-5042.
  • the compounds according to the invention are administered in combination with a cholesterol absorption inhibitor, such as by way of example and preferably ezetimibe, tiqueside or pamaqueside.
  • a cholesterol absorption inhibitor such as by way of example and preferably ezetimibe, tiqueside or pamaqueside.
  • the compounds according to the invention are administered in combination with a lipase inhibitor, such as, for example and preferably, orlistat.
  • a lipase inhibitor such as, for example and preferably, orlistat.
  • the compounds according to the invention are administered in combination with a polymeric bile acid adsorbent, such as by way of example and preferably cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.
  • a polymeric bile acid adsorbent such as by way of example and preferably cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.
  • ASBT IBAT
  • the compounds according to the invention are administered in combination with a lipoprotein (a) antagonist, such as, by way of example and by way of preference, gemcabene calcium (CI-1027) or nicotinic acid.
  • a lipoprotein (a) antagonist such as, by way of example and by way of preference, gemcabene calcium (CI-1027) or nicotinic acid.
  • compositions containing at least one compound of the invention usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and their use for the purposes mentioned above.
  • the compounds according to the invention can act systemically and / or locally.
  • they may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, otic or as an implant or stent.
  • the compounds according to the invention can be administered in suitable administration forms.
  • the compounds of the invention rapidly and / or modified donating application forms containing the compounds of the invention in crystalline and / or amorphous and / or dissolved form, such as tablets (uncoated or coated Tablets, for example with enteric or delayed dissolving the or insoluble coatings which control the release of the compound of the invention), orally disintegrating tablets or films / wafers, films / lyophilisates, capsules (for example hard or soft gelatin capsules), dragees, granules, pellets, powders, emulsions, suspensions, Aerosols or solutions.
  • tablets uncoated or coated Tablets, for example with enteric or delayed dissolving the or insoluble coatings which control the release of the compound of the invention
  • Parenteral administration can be done bypassing a resorption step (eg intravenously, intraarterially, intracardially, intraspinally or intralumbarly) or using absorption (for example by inhalation, intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally).
  • a resorption step eg intravenously, intraarterially, intracardially, intraspinally or intralumbarly
  • absorption for example by inhalation, intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally.
  • suitable application forms include injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • inhalation medicaments including powder inhalers, nebulizers, aerosols
  • nasal drops solutions or sprays
  • lingual, sublingual or buccal tablets to be applied
  • films / wafers or capsules films / wafers or capsules, suppositories, ear or eye preparations
  • vaginal capsules aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (eg plasters), milk, pastes, foams, powdered powders, implants or stents.
  • Preference is given to oral or parenteral administration, in particular oral, intravenous and inhalative administration.
  • the compounds according to the invention can be converted into the stated administration forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients.
  • These adjuvants include, among others. Carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (for example liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecyl sulfate, polyoxysorbitanoleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers ( For example, antioxidants such as ascorbic acid), dyes (eg, inorganic pigments such as iron oxides) and flavor and / or odoriferous.
  • Carriers for example microcrystalline cellulose, lactose, mannitol
  • solvents for example liquid polyethylene glycols
  • emulsifiers and dispersants or wetting agents for example sodium dodecy
  • the dosage is about 0.01 to 100 mg / kg, preferably about 0.01 to 20 mg / kg and most preferably 0.1 to 10 mg / kg of body weight.
  • Method 1 Instrument: Waters ACQUITY SQD UPLC System; Column: Waters Acquity UPLC HSS T3 1.8 ⁇ 50 x 1 mm; Eluent A: 1 l of water + 0.25 ml of 99% formic acid, eluent B: 1 l of acetonitrile + 0.25 ml of 99% formic acid; Gradient: 0.0 min 90% A -> 1.2 min 5% A -> 2.0 min 5% A Furnace: 50 ° C; Flow: 0.40 ml / min; UV detection: 210 - 400 nm.
  • Method 2 Device Type MS: Waters (Micromass) Quattro Micro; Device type HPLC: Agilent 1100 series; Column: Thermo Hypersil GOLD 3 ⁇ 20 x 4 mm; Eluent A: 1 l of water + 0.5 ml of 50% formic acid, eluent B: 1 l of acetonitrile + 0.5 ml of 50% formic acid; Gradient: 0.0 min 100% A-> 3.0 min 10% A-> 4.0 min 10% A -> 4.01 min 100% A (flow 2.5 ml) -> 5.00 min 100% A; Oven: 50 ° C; Flow: 2 ml / min; UV detection: 210 nm.
  • Method 3 Instrument: Micromass Quattro Premier with Waters UPLC Acquity; Column: Thermo Hypersil GOLD 1.9 ⁇ 50 x 1 mm; Eluent A: 1 l of water + 0.5 ml of 50% formic acid, eluent B: 1 l of acetonitrile + 0.5 ml of 50% formic acid; Gradient: 0.0 min 90% A -> 0.1 min 90% A -> 1.5 min 10% A-> 2.2 min 10% A Furnace: 50 ° C; Flow: 0.33 ml / min; UV detection: 210 nm.
  • Method 4 Instrument: Micromass Quattro Premier with Waters UPLC Acquity; Column: Thermo Hypersil GOLD 1.9 ⁇ 50 x 1 mm; Eluent A: 1 l of water + 0.5 ml of 50% formic acid, eluent B: 1 l of acetonitrile + 0.5 ml of 50% formic acid; Gradient: 0.0 min 97% A -> 0.5 min 97% A -> 3.2 min 5% A -> 4.0 min 5% A Oven: 50 ° C; Flow: 0.3 ml / min; UV detection: 210 nm.
  • Method 5 Instrument: Waters ACQUITY SQD UPLC System; Column: Waters Acquity UPLC HSS T3 1.8 ⁇ 30 x 2 mm; Eluent A: 1 l of water + 0.25 ml of 99% formic acid, eluent B: 1 l of acetonitrile + 0.25 ml of 99% formic acid; Gradient: 0.0 min 90% A -> 1.2 min 5% A -> 2.0 min 5% A Furnace: 50 ° C; Flow: 0.60 ml / min; UV detection: 208-400 nm.
  • Method 7 (preparative HPLC): Column: Reprosil C18, 10 ⁇ m, 250 mm ⁇ 30 mm. Eluent A: formic acid 0.1% in water, eluent B: acetonitrile; Flow: 50 ml / min; Program: 0 to 6 min: 90% A / 10% B; 6 min to 27 min: gradient to 95% B; 27 minutes to 38 minutes 95% B; 38 min to 39 min gradient to 10% B; 39 min to 43 min (end): 60% A / 40% B. Slight deviations of the gradient are possible.
  • Method 8 (preparative HPLC): column: Reprosil C18, 10 ⁇ m, 250 mm ⁇ 30 mm.
  • Eluent A formic acid 0.1% in water, eluent B: methanol; Flow: 50 ml / min; Program: 0 to 4.25 min: 60% A / 40% B; 4.25 to 4.50 min: gradient to 60% B; 4.50 min to 17 min gradient to 100% B; 17 min to 19.50 min 100% B; 19.50 min to 19.75 min gradient to 40% B; 19.75 to 22 minutes (end): 60% A / 40% B. Slight deviations of the gradient are possible.
  • Method 9 (Preparative HPLC): Column: Sunfire C18, 5 ⁇ m, 250 mm ⁇ 20 mm. Eluent methanol / TFA 1% in water 50/50; Flow: 25 ml / min; Detection 210 nm, temperature 40 ° C.
  • Method 10 (preparative HPLC): Column: Sunfire C18, 5 ⁇ m, 250 mm ⁇ 20 mm. Eluent acetonitrile / TFA 1% in water 55/45; Flow: 25 ml / min; Detection 210 nm, temperature 40 ° C.
  • Method 11 (preparative HPLC): Column: Reprosil C18, 10 ⁇ m, 250 mm ⁇ 40 mm. Eluent A: formic acid 0.1% in water, eluent B: acetonitrile; Flow: 50 ml / min. Program: 0-6 min: 90% A / 10% B; 6-40 min: gradient to 95% B; 40-53 min: 5% A / 95% B; 53.01-54 min: gradient to 10% B; 54.01-57 min: 90% A / 10% B.
  • Method 12 (chiral preparative HPLC): column Daicel Chiralpak AD-H 250 mm x 20 mm; Flow: 20 ml / min; Eluent: where-propanol / ethanol / hexane 15:15:70 (v / v / v); Detector 230 nm.
  • Method 13 (chiral analytical HPLC): column Daicel Chiralpak AD-H 5 ⁇ , 250 mm x 4.6 mm; Temperature 30 ° C; Flow: 1 ml / min; Eluent: where-propanol / ethanol / hexane 15:15:70 (v / v / v); Detector 220 nm.
  • Method 14 (chiral analytical HPLC): column Daicel Chiralpak AS-H 5 ⁇ , 250 mm x 4.6 mm; Temperature 30 ° C; Flow: 1 ml / min; Eluent: ethanol / hexane 50:50 mixed with 1% water and 0.2% trifluoroacetic acid; Detector 220 nm.
  • Method 15 (preparative HPLC): Same as Method 7 but with Chromatorex C18 column 250 mm x 30 mm.
  • Method 17 (chiral analytical HPLC): column Daicel Chiralpak AZ-H 5 ⁇ , 250 mm x 4.6 mm; Temperature 40 ° C; Flow: 1 ml / min; Eluent: ethanol / hexane 50:50 (v / v) added with 1% water and 0.2% trifluoroacetic acid; Detector 220 nm.
  • Method 18 (chiral preparative HPLC) :: column Daicel Chiralpak AD-H 250 mm x 20 mm; Flow: 20 ml / min; Eluent: where-propanol / hexane 50:50 (v / v) added with 1% water and 0.2% trifluoroacetic acid; Detector 230 nm.
  • Method 21 (chiral analytical HPLC): column Daicel Chiralpak AD-H 5 ⁇ , 250 mm x 4.6 mm; Temperature 40 ° C; Flow: 1 ml / min; Eluent: ethanol / hexane 70:30 (v / v) added with 1% water and 0.2% trifluoroacetic acid; Detector 220 nm.
  • Method 22 (preparative HPLC): column: Sunfire C18, 5 ⁇ m, 250 mm ⁇ 20 mm. Eluent acetonitrile water 60:40; Flow: 25 ml / min; Detection 210 nM, temperature 40 ° C.
  • Method 24 (preparative HPLC): Column: Sunfire C18, 5 ⁇ m, 75 mm ⁇ 30 mm. Eluent acetonitrile / 0.05% TFA in water 1:99 to 2.25 min, then acetonitrile / 1% TFA in water 95: 5; Flow: 60 ml / min; Detection 210 nM, temperature 40 ° C.
  • Method 25 (chiral analytical HPLC): column Daicel Chiralpak AD-H 5 ⁇ , 250 mm x 4.6 mm; Temperature 30 ° C; Flow: 1 ml / min; Eluent: / so-propanol / iso-hexane 5:95 (v / v); Detector 220 nm.
  • Method 26 MS, Instrument: Thermo Fisher-Scientific DSQ; chemical ionization; Reactant gas NH 3 ; Source temperature: 200 ° C; Ionization energy 70eV.
  • Method 27 chiral analytical HPLC: column Daicel Chiralpak AD-H 5 ⁇ , 250 mm x 4.6 mm; Temperature 30 ° C; Flow: 1 ml / min; Eluent: where-propanol / ethanol / hexane 25: 25: 50 (v / v / v); Detector 220 nm.
  • Method 28 MCW_SQ-HSST3_long Instrument: Waters ACQUITY SQD UPLC System; Column: Waters Acquity UPLC HSS T3 1.8 ⁇ 50 x 1 mm; Eluent A: 1 l of water + 0.25 ml of 99% formic acid, eluent B: 1 l of acetonitrile + 0.25 ml of 99% formic acid; Gradient: 0.0 min 95% A-> 6.0 min 5% A-> 7.5 min 5% A; Oven: 50 ° C; Flow: 0.35 ml / min; UV detection: 210 - 400 nm.
  • Method 30 (chiral analytical HPLC): column Daicel Chiralpak IC 5 ⁇ , 250 mm x 4.6 mm; Flow: 1 ml / min; Temperature 30 ° C; Detector: 220 nm; Eluent: acetonitrile / MTBE 50:50 (v / v).
  • Method 31 (chiral preparative HPLC): column Daicel Chiralpak LA 5 ⁇ m, 250 mm ⁇ 20 mm; Flow: 20 ml / min; Temperature 30 ° C; Detector: 285 nm; Eluent: acetonitrile / MTBE 50:50 (v / v).
  • Method 32 (chiral analytical HPLC): column Daicel Chiralpak IA 5 ⁇ , 250 mm x 4.6 mm; Flow: 1 ml / min; Temperature 30 ° C; Detector: 285 nm; Eluent: acetonitrile / MTBE 50:50 (v / v).
  • Method 33 (chiral preparative HPLC): column Daicel Chiralpak IA 5 ⁇ , 250 mm x20 mm; Flow: 20 ml / min; Temperature 30 ° C; Detector: 285 nm; Eluent: acetonitrile / MTBE 20:80 (v / v).
  • reaction mixture was concentrated under reduced pressure, acidified with 1M hydrochloric acid (80 ml) and extracted three times with 80 ml of ethyl acetate each time.
  • the veeinippon organic phases were dried over sodium sulfate, filtered and the filtrate was concentrated.
  • the residue was chromatographed on silica gel (petroleum ether / ethyl acetate 3: 1 to 1: 3). 4.20 g (56% of theory) of the title compound were obtained.
  • the preparation of the target compound was carried out analogously to Example 25 A using 1.00 g (6.71 mmol) of 5-amino-l, 3-dihydro-2H-benzimidazol-2-one and 1.74 g (6.71 mmol) of ethyl 3-ethoxy-2 - [(ethoxycarbonyl) carbamoyl] acrylate. 1.60 g (75% of theory) of the target compound were obtained.
  • Emyl-1- (6-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl) -2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
  • reaction mixture was mixed with water and acidified with 1N hydrochloric acid.
  • the resulting solid was filtered off, washed with water and ethyl acetate, and then dried in vacuo at 50.degree. This gave 1.46 g (72% of theory) of the target compound.
  • reaction mixture was diluted with water, acidified with 1M hydrochloric acid and the resulting solid was filtered off. The solid was washed with water and ethyl acetate and dried in vacuo at 50 ° C overnight. 736 mg (85% of theory) of the target compound were obtained.
  • Emyl-1- (3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl) -2,4-dioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylate
  • reaction mixture was filtered through diatomaceous earth at RT, washed with ethyl acetate / methanol (1: 1) and the filtrate was concentrated. The residue was mixed with water, the precipitated solid was filtered off, washed with water and dried at 50 ° C in a vacuum. 546 mg (47% of theory) of the title compound were obtained.
  • Example 27A Preparation and purification of the target compound were carried out analogously to Example 27A. Starting from 612 mg (3.49 mmol) of 1-isopropyl-1H-benzimidazole-5-amine from Example 50A and 905 mg (3.49 mmol) of ethyl 3-ethoxy-2 - [(ethoxycarbonyl) carbamoyl] acrylate, 684 mg of 57% of theory) of the title compound.
  • Emyl-2,4-dio-1- (1,3,3-trimemyl-2-oxo-2,3-dihydro-1H-indol-6-yl) -1,2,3,4-tetrahydropyrimidine-5 carboxylate
  • reaction mixture was treated with water, acidified with 1N hydrochloric acid and extracted twice with ethyl acetate.
  • the combined organic phases were dried over magnesium sulphate, filtered and concentrated.
  • the residue was triturated with MTBE / ethyl acetate, filtered off, washed with ethyl acetate and then dried at 50 ° C. in vacuo.
  • the precipitated in the filtrate solid was filtered off and dried in vacuo. A total of 388 mg (68% of theory) of the title compound were obtained.
  • reaction mixture was treated with water, acidified with 1N hydrochloric acid and extracted twice with ethyl acetate.
  • the combined organic phases were dried over magnesium sulfate, filtered and concentrated.
  • the residue was stirred in MTBE / ethyl acetate, the resulting solid was filtered off, washed with ethyl acetate and then dried in vacuo at 50 ° C. 630 mg (79% of theory) of the title compound were obtained.
  • the mixture was poured into 200 ml of 1N hydrochloric acid and extracted three times with ethyl acetate.
  • the combined organic phases were washed with water, then a saturated sodium chloride solution, dried over sodium sulfate and concentrated on a rotary evaporator.
  • the residue was dissolved in 200 ml of acetonitrile and the mineral oil extracted with n-pentane.
  • the separated acetonitrile phase was concentrated on a rotary evaporator and dried the remaining brownish solid in HV. 4.45 g (84% of theory) of the title compound were obtained in 91% purity.
  • diethylaminosulfur trifluoride (0.5 eq.) was added again at -78 ° C and stirred for 1 h at RT.
  • diethylaminosulfur trifluoride (0.5 eq.) was added again at -78 ° C and stirred for 1 h at RT.
  • the mixture was diluted with dichloromethane, washed once each with saturated sodium bicarbonate solution and saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated. 191 mg (91% of theory) of the title compound were obtained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/EP2013/059286 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung WO2013167495A1 (de)

Priority Applications (34)

Application Number Priority Date Filing Date Title
UAA201413167A UA112897C2 (uk) 2012-05-09 2013-03-05 Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
CA2872906A CA2872906C (en) 2012-05-09 2013-05-03 Bicyclically substituted uracils and the use thereof
JP2015510754A JP6141414B2 (ja) 2012-05-09 2013-05-03 二環で置換されたウラシル類およびそれの使用
DK13720407.9T DK2847190T3 (en) 2012-05-09 2013-05-03 BICYCLICALLY SUBSTITUTED URACILS AND USE THEREOF
AU2013258223A AU2013258223B2 (en) 2012-05-09 2013-05-03 Bicyclically substituted uracils and the use thereof
KR1020147034155A KR102083281B1 (ko) 2012-05-09 2013-05-03 비시클릭 치환된 우라실 및 그의 용도
ES13720407.9T ES2581537T3 (es) 2012-05-09 2013-05-03 Uracilos sustituidos bicíclicamente y su uso
EA201492040A EA030383B9 (ru) 2012-05-09 2013-05-03 Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
MX2018008811A MX367599B (es) 2012-05-09 2013-05-03 Uracilos sustituidos bicíclicamente y uso de los mismos.
NZ701700A NZ701700A (en) 2012-05-09 2013-05-03 Bicyclically substituted uracils and the use thereof
EP13720407.9A EP2847190B1 (de) 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung
CN201380034776.9A CN104395310B (zh) 2012-05-09 2013-05-03 二环取代尿嘧啶及其用途
BR112014028086-0A BR112014028086B1 (pt) 2012-05-09 2013-05-03 Uracilas biciclicamente substituídas, seu processo de preparação, e medicamento
RS20160510A RS54901B1 (sr) 2012-05-09 2013-05-03 Biciklično supstituisani uracili i njihova upotreba
SI201330233A SI2847190T1 (sl) 2012-05-09 2013-05-03 Biciklično substituirani uracili in njihova uporaba
US14/399,945 US9481672B2 (en) 2012-05-09 2013-05-03 Bicyclically substituted uracils and the use thereof
MX2014013571A MX357712B (es) 2012-05-09 2013-05-03 Uracilos sustituidos bicíclicamente y uso de los mismos.
AP2014008096A AP2014008096A0 (en) 2012-05-09 2013-05-03 Bicyclically substituted uracils and the use thereof
MYPI2014703273A MY181828A (en) 2012-05-09 2013-05-03 Bicyclically substituted uracils and the use therapy
IL235438A IL235438A (en) 2012-05-09 2014-11-02 Uracils are stored in the bicycle and used
CU2014000129A CU20140129A7 (es) 2012-05-09 2014-11-06 Uracilos sustituidos bicíclicamente y uso de los mismos
CR20140513A CR20140513A (es) 2012-05-09 2014-11-07 Uracilos sustituidos bicíclicamente y uso de los mismos
ZA2014/08146A ZA201408146B (en) 2012-05-09 2014-11-07 Bicyclically substituted uracils and the use thereof
PH12014502496A PH12014502496A1 (en) 2012-05-09 2014-11-07 Bicyclically substituted uracils and the use thereof
TN2014000470A TN2014000470A1 (en) 2012-05-09 2014-11-07 Bicyclically substituted uracils and the use thereof
HK15103474.2A HK1202873A1 (en) 2012-05-09 2015-04-09 Bicyclically substituted uracils and the use thereof
HRP20160796TT HRP20160796T1 (hr) 2012-05-09 2016-07-06 Biciklički supstituirani uracili i njihovo korištenje
CY20161100636T CY1118900T1 (el) 2012-05-09 2016-07-06 Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
US15/288,982 US9949978B2 (en) 2012-05-09 2016-10-07 Bicyclically substituted uracils and the use thereof
US15/288,968 US9949977B2 (en) 2012-05-09 2016-10-07 Bicyclically substituted uracils and the use thereof
IL253950A IL253950B (en) 2012-05-09 2017-08-10 Cyclic-converted uracils and their use
AU2017265047A AU2017265047B2 (en) 2012-05-09 2017-11-22 Bicyclically substituted uracils and the use thereof
US15/912,185 US10300062B2 (en) 2012-05-09 2018-03-05 Bicyclically substituted uracils and the use thereof
US16/373,487 US20200061063A1 (en) 2012-05-09 2019-04-02 Bicyclically substituted uracils and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167231 2012-05-09
EP12167231.5 2012-05-09

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/399,945 A-371-Of-International US9481672B2 (en) 2012-05-09 2013-05-03 Bicyclically substituted uracils and the use thereof
US15/288,982 Continuation US9949978B2 (en) 2012-05-09 2016-10-07 Bicyclically substituted uracils and the use thereof
US15/288,968 Continuation US9949977B2 (en) 2012-05-09 2016-10-07 Bicyclically substituted uracils and the use thereof

Publications (1)

Publication Number Publication Date
WO2013167495A1 true WO2013167495A1 (de) 2013-11-14

Family

ID=48289199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/059286 WO2013167495A1 (de) 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung

Country Status (44)

Country Link
US (5) US9481672B2 (nl)
EP (2) EP3045456B1 (nl)
JP (2) JP6141414B2 (nl)
KR (1) KR102083281B1 (nl)
CN (2) CN106983751B (nl)
AP (1) AP2014008096A0 (nl)
AR (1) AR090994A1 (nl)
AU (2) AU2013258223B2 (nl)
BR (1) BR112014028086B1 (nl)
CA (1) CA2872906C (nl)
CL (1) CL2014003031A1 (nl)
CO (1) CO7131375A2 (nl)
CR (1) CR20140513A (nl)
CU (1) CU20140129A7 (nl)
CY (2) CY1118900T1 (nl)
DK (2) DK2847190T3 (nl)
DO (1) DOP2014000255A (nl)
EA (2) EA030383B9 (nl)
EC (1) ECSP14026138A (nl)
ES (2) ES2581537T3 (nl)
HK (1) HK1202873A1 (nl)
HR (2) HRP20160796T1 (nl)
HU (2) HUE035462T2 (nl)
IL (2) IL235438A (nl)
JO (1) JO3290B1 (nl)
LT (1) LT3045456T (nl)
MX (2) MX357712B (nl)
MY (1) MY181828A (nl)
NO (1) NO3045456T3 (nl)
NZ (1) NZ701700A (nl)
PE (1) PE20142301A1 (nl)
PH (1) PH12014502496A1 (nl)
PL (2) PL2847190T3 (nl)
PT (2) PT2847190T (nl)
RS (2) RS56784B1 (nl)
SA (1) SA113340533B1 (nl)
SG (1) SG10202003175QA (nl)
SI (2) SI3045456T1 (nl)
TN (1) TN2014000470A1 (nl)
TW (2) TWI635085B (nl)
UA (1) UA112897C2 (nl)
UY (1) UY34797A (nl)
WO (1) WO2013167495A1 (nl)
ZA (1) ZA201408146B (nl)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015067630A1 (de) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
WO2015067650A1 (de) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte 1,2,4-triazin-3,5-dione und ihre verwendung als chymase hemmern
WO2015067652A1 (de) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
WO2018197333A1 (en) 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
WO2019219672A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2023194222A1 (en) 2022-04-05 2023-10-12 Socpra Sciences Santé Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
JP2016535769A (ja) * 2013-11-08 2016-11-17 バイエル ファーマ アクチエンゲゼルシャフト キマーゼ阻害薬としての置換されているウラシル類
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
CN113811530B (zh) * 2019-07-03 2022-07-19 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN111440141A (zh) * 2020-05-20 2020-07-24 安徽泽升科技有限公司 一种羟甲基取代芳杂环类化合物的制备方法
WO2022135534A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
CN114685472B (zh) * 2020-12-25 2024-04-26 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
WO2023107470A1 (en) * 2021-12-06 2023-06-15 Pretzel Therapeutics, Inc. Lonp1 inhibitors, uses and methods

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006569A1 (de) 1998-07-29 2000-02-10 Bayer Aktiengesellschaft Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate
WO2000006568A1 (de) 1998-07-29 2000-02-10 Bayer Aktiengesellschaft Substituierte pyrazolderivate
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
WO2001019355A2 (de) 1999-09-13 2001-03-22 Bayer Aktiengesellschaft Dicarbonsäurederivate mit neuartigen pharmazeutischen eigenschaften
WO2001019778A1 (de) 1999-09-13 2001-03-22 Bayer Aktiengesellschaft Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2001019780A2 (de) 1999-09-13 2001-03-22 Bayer Aktiengesellschaft Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2001019776A2 (de) 1999-09-13 2001-03-22 Bayer Aktiengesellschaft Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2002042301A1 (de) 2000-11-22 2002-05-30 Bayer Aktiengesellschaft Neue pyridin-substituierte pyrazolopyridinderivate
WO2002070510A2 (de) 2001-03-07 2002-09-12 Bayer Aktiengesellschaft Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2002070462A1 (de) 2001-03-07 2002-09-12 Bayer Aktiengesellschaft Substituierte aminodicarbonsäurederivate
WO2003072553A1 (en) 2002-02-25 2003-09-04 Pharmacia & Upjohn Company N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
WO2003095451A1 (de) 2002-05-08 2003-11-20 Bayer Healthcare Ag Carbamat-substituierte pyrazolopyridine
US20040102384A1 (en) * 2000-08-30 2004-05-27 Takashi Deguchi Pyrrolidine derivatives and their use as chymase inhibitor
WO2004052858A2 (en) 2002-12-06 2004-06-24 Eli Lilly And Company Inhibitors of monoamine uptake
WO2005072741A1 (de) 2004-01-31 2005-08-11 Bayer Healthcare Ag ((11-oxo-10,11-dihydrodibenzo [b, f] [1, 4] oxazepin-1-yl)oxy) essigsäure-derivate und verwandte verbindungen als herz-kreislaufmittel zur behandlung von atherosclerose
WO2005092899A1 (en) 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
WO2006012374A1 (en) 2004-07-22 2006-02-02 Amgen Inc. Substituted aryl-amine derivatives and methods of use
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
US20060258689A1 (en) 2005-05-04 2006-11-16 Kelly Michael G Fused heterocyclic compounds, and compositions and uses thereof
WO2007093904A1 (en) 2006-02-14 2007-08-23 Pfizer Products Inc. Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
WO2007150011A2 (en) 2006-06-23 2007-12-27 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US20080090856A1 (en) 2006-10-11 2008-04-17 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2008056257A2 (en) 2006-11-10 2008-05-15 Addex Pharma S.A Novel triazinedione derivatives as gaba-b receptor modulators
WO2008103277A2 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
WO2008128009A2 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009156182A2 (de) 2008-06-25 2009-12-30 Resprotect Gmbh Uracilderivate und deren verwendung
US20100305102A1 (en) 2007-10-19 2010-12-02 Boehringer Ingelheim International Gmbh Heterocycle-substituted piperazino-dihydrothienopyrimidines
US20110053974A1 (en) 2008-06-25 2011-03-03 Daiichi Sankyo Company, Limited Carboxylic acid compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
AU6868900A (en) 1999-09-03 2001-04-10 Ajinomoto Co., Inc. Novel processes for preparing oxazepine derivatives
JP2003017508A (ja) 2001-07-05 2003-01-17 Nec Corp 電界効果トランジスタ
JP2003342265A (ja) * 2002-05-22 2003-12-03 Senju Pharmaceut Co Ltd トリアゾリジン誘導体およびその医薬用途
WO2005018672A1 (ja) * 2003-08-22 2005-03-03 Teijin Pharma Limited キマーゼ阻害剤を有効成分として含有する薬剤
WO2007007161A2 (en) * 2005-07-08 2007-01-18 Orchid Research Laboratories Limited Novel bio-active derivatives
SG192543A1 (en) * 2008-05-05 2013-08-30 Merck Canada Inc 3, 4 - substituted piperidine derivatives as renin inhibitors
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
WO2000006569A1 (de) 1998-07-29 2000-02-10 Bayer Aktiengesellschaft Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate
WO2000006568A1 (de) 1998-07-29 2000-02-10 Bayer Aktiengesellschaft Substituierte pyrazolderivate
WO2001019776A2 (de) 1999-09-13 2001-03-22 Bayer Aktiengesellschaft Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2001019778A1 (de) 1999-09-13 2001-03-22 Bayer Aktiengesellschaft Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2001019780A2 (de) 1999-09-13 2001-03-22 Bayer Aktiengesellschaft Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2001019355A2 (de) 1999-09-13 2001-03-22 Bayer Aktiengesellschaft Dicarbonsäurederivate mit neuartigen pharmazeutischen eigenschaften
US20040102384A1 (en) * 2000-08-30 2004-05-27 Takashi Deguchi Pyrrolidine derivatives and their use as chymase inhibitor
WO2002042301A1 (de) 2000-11-22 2002-05-30 Bayer Aktiengesellschaft Neue pyridin-substituierte pyrazolopyridinderivate
WO2002070510A2 (de) 2001-03-07 2002-09-12 Bayer Aktiengesellschaft Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2002070462A1 (de) 2001-03-07 2002-09-12 Bayer Aktiengesellschaft Substituierte aminodicarbonsäurederivate
WO2003072553A1 (en) 2002-02-25 2003-09-04 Pharmacia & Upjohn Company N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
WO2003095451A1 (de) 2002-05-08 2003-11-20 Bayer Healthcare Ag Carbamat-substituierte pyrazolopyridine
WO2004052858A2 (en) 2002-12-06 2004-06-24 Eli Lilly And Company Inhibitors of monoamine uptake
WO2005072741A1 (de) 2004-01-31 2005-08-11 Bayer Healthcare Ag ((11-oxo-10,11-dihydrodibenzo [b, f] [1, 4] oxazepin-1-yl)oxy) essigsäure-derivate und verwandte verbindungen als herz-kreislaufmittel zur behandlung von atherosclerose
WO2005092899A1 (en) 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
WO2006012374A1 (en) 2004-07-22 2006-02-02 Amgen Inc. Substituted aryl-amine derivatives and methods of use
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
US20060258689A1 (en) 2005-05-04 2006-11-16 Kelly Michael G Fused heterocyclic compounds, and compositions and uses thereof
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
WO2007093904A1 (en) 2006-02-14 2007-08-23 Pfizer Products Inc. Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents
WO2007150011A2 (en) 2006-06-23 2007-12-27 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US20080090856A1 (en) 2006-10-11 2008-04-17 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2008056257A2 (en) 2006-11-10 2008-05-15 Addex Pharma S.A Novel triazinedione derivatives as gaba-b receptor modulators
WO2008103277A2 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
WO2008128009A2 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US20100305102A1 (en) 2007-10-19 2010-12-02 Boehringer Ingelheim International Gmbh Heterocycle-substituted piperazino-dihydrothienopyrimidines
WO2009156182A2 (de) 2008-06-25 2009-12-30 Resprotect Gmbh Uracilderivate und deren verwendung
US20110053974A1 (en) 2008-06-25 2011-03-03 Daiichi Sankyo Company, Limited Carboxylic acid compound

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
BACANI; FRISHMAN, CARDIOL. REV., vol. 14, no. 4, 2006, pages 187 - 193
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 14, no. 18, 2006, pages 6434 - 6443
CIRCULATION RESEARCH, vol. 41, 1977, pages 19 - 26
DOGRELL S. A., EXPERT OPIN. THER. PATENTS, vol. 18, 2008, pages 485 - 499
FLEMING 1., CIRC. RES., vol. 98, 2006, pages 887 - 896
H. NISHIYAMA ET AL., CHEM. EUR. J., vol. 12, no. 1, 2006, pages 63 - 71
HUANG ET AL., J. AM. SOC. NEPHROL., vol. 14, no. 7, 2003, pages 1738 - 1747
HUGHES, D. L., ORG. PREP. PROCEED. INT., vol. 28, 1996, pages 127
HUGHES, D. L.: "Organic Reactions", vol. 42, 1992, JOHN WILEY & SONS, LTD, article "The Mitsunobu Reaction", pages: 335
J. HET. CHEM., vol. 29, no. 5, 1992, pages 1069 - 1076
JIN ET AL., LIFE SCI., vol. 71, 2002, pages 437 - 446
JIN ET AL., PHARMACOL. EXP. THER., vol. 309, 2004, pages 409 - 417
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 45, no. 4, 2008, pages 969 - 973
JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 7, 1989, pages 1481 - 1491
JOURNAL OF ORGANIC CHEMISTRY, vol. 65, no. 24, 2000, pages 8317 - 8325
KOVANEN ET AL., CIRCULATION, vol. 92, 1995, pages 1084 - 1088
LIBBY; SHI, CIRCULATION, vol. 115, 2007, pages 2555 - 2558
MATSUMOTO ET AL., CIRCULATION, vol. 107, 2003, pages 2555 - 2558
MCPHERSON ET AL., J. AM. SOC. NEPHROL., vol. 15, no. 2, 2004, pages 493 - 500
MIYAZAKI ET AL., PHARMACOL. THER., vol. 112, 2006, pages 668 - 676
NASR, M. ET AL., J. MED. CHEM., vol. 31, no. 7, 1988, pages 1347 - 1351
SAMUEL J. DANISHEFSKY ET AL: "Total synthesis of octosyl acid A. Intramolecular Williamson reaction via a cyclic stannylene derivative", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 110, no. 22, 1 October 1988 (1988-10-01), pages 7434 - 7440, XP055066600, ISSN: 0002-7863, DOI: 10.1021/ja00230a024 *
SENDA, SHIGEO; HIROTA, KOSAKU; NOTANI, JIYOJI, CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 20, no. 7, 1972, pages 1380 - 1388
SENDA, SHIGEO; HIROTA, KOSAKU; NOTANI, JIYOJI, CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 20, no. 7, 1972, pages 1380 - 8
SHIOTA ET AL., J. HYPERTENS, vol. 21, 2003, pages 1823 - 1825
TAKAI ET AL., JPN. J. PHARMACOL., vol. 86, 2001, pages 124 - 126
TETRAHEDRON, vol. 58, no. 2, 2002, pages 295 - 308
ZANINI ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 120, 2007, pages 329 - 333
ZHURNAL ORGANICHESKOI KHIMII, vol. 9, no. 5, 1973, pages 1019 - 1024,1046-1050

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658647B (zh) * 2013-11-08 2019-09-06 拜耳医药股份有限公司 化合物的盐
KR20160078980A (ko) * 2013-11-08 2016-07-05 바이엘 파마 악티엔게젤샤프트 1-(3-메틸-2-옥소-2,3-디히드로-1,3-벤족사졸-6-일)-2,4-디옥소-3-[(1r)-4-(트리플루오르메틸)-2,3-디히드로-1h-인덴-1-일]-1,2,3,4-테트라히드로피리미딘-5-카르복실산의 염
KR102351418B1 (ko) 2013-11-08 2022-01-17 바이엘 파마 악티엔게젤샤프트 1-(3-메틸-2-옥소-2,3-디히드로-1,3-벤족사졸-6-일)-2,4-디옥소-3-[(1r)-4-(트리플루오르메틸)-2,3-디히드로-1h-인덴-1-일]-1,2,3,4-테트라히드로피리미딘-5-카르복실산의 염
WO2015067630A1 (de) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
AU2014345599B2 (en) * 2013-11-08 2019-02-14 Bayer Pharma Aktiengesellschaft Salts of 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)- 4-(trifluormethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid
US20160289220A1 (en) * 2013-11-08 2016-10-06 Bayer Pharma Aktiengesellschaft Novel salts
US9751843B2 (en) 2013-11-08 2017-09-05 Bayer Pharma Aktiengesellschaft Substituted uracils and use thereof
US9926305B2 (en) * 2013-11-08 2018-03-27 Bayer Pharma Aktiengesellschaft Salts
EA033132B1 (ru) * 2013-11-08 2019-08-30 Байер Фарма Акциенгезельшафт Соли 1-(3-метил-2-оксо-2,3-дигидро-1,3-бензоксазол-6-ил)-2,4-диоксо-3-[(1r)-4-(трифторометил)-2,3-дигидро-1h-инден-1-ил]-1,2,3,4-тетрагидропиримидин-5-карбоновой кислоты
CN105658647A (zh) * 2013-11-08 2016-06-08 拜耳医药股份有限公司 1-(3-甲基-2-氧代-2,3-二氢-1,3-苯并噁唑-6-基)-2,4-二氧代-3-[(1r)-4-(三氟甲基)-2,3-二氢-1h-茚-1-基]-1,2,3,4-四氢嘧啶-5-甲酸的盐
WO2015067652A1 (de) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure
WO2015067650A1 (de) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte 1,2,4-triazin-3,5-dione und ihre verwendung als chymase hemmern
WO2018114514A1 (de) 2016-12-20 2018-06-28 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
IL266823A (en) * 2016-12-20 2019-07-31 Bayer Pharma AG Use of chymase inhibitors to treat endometriosis, post-operative fibrosis and diseases associated with fibrosis formation
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CN110072527A (zh) * 2016-12-20 2019-07-30 拜耳制药股份公司 胃促胰酶抑制剂在治疗子宫内膜异位、术后纤维化和以纤维化形成为特征的疾病中的用途
US11266646B2 (en) 2016-12-20 2022-03-08 Bayer Pharma Aktiengesellschaft Use of chymase inhibitors for the treatment of endometriosis, post operative fibrosis and diseases which are characterized by fibrosis formation
WO2018197333A1 (en) 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
WO2019219672A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2023194222A1 (en) 2022-04-05 2023-10-12 Socpra Sciences Santé Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders

Also Published As

Publication number Publication date
CY1118900T1 (el) 2018-01-10
MX357712B (es) 2018-07-20
JP2017160242A (ja) 2017-09-14
CN106983751B (zh) 2020-01-07
JP6367421B2 (ja) 2018-08-01
AU2017265047B2 (en) 2019-04-18
TW201734007A (zh) 2017-10-01
EP2847190A1 (de) 2015-03-18
US10300062B2 (en) 2019-05-28
IL253950A0 (en) 2017-10-31
IL235438A (en) 2017-08-31
US20170020876A1 (en) 2017-01-26
HRP20180125T1 (hr) 2018-02-23
EA201790032A1 (ru) 2017-05-31
KR102083281B1 (ko) 2020-05-29
MX367599B (es) 2019-08-28
UA112897C2 (uk) 2016-11-10
CA2872906C (en) 2020-08-04
ES2657315T3 (es) 2018-03-02
TWI579278B (zh) 2017-04-21
JP6141414B2 (ja) 2017-06-07
AU2017265047A1 (en) 2017-12-14
CN104395310A (zh) 2015-03-04
DK3045456T3 (da) 2018-01-29
EA201492040A1 (ru) 2015-12-30
US20200061063A1 (en) 2020-02-27
PH12014502496B1 (en) 2015-01-12
SI2847190T1 (sl) 2016-08-31
HUE029366T2 (en) 2017-02-28
US9481672B2 (en) 2016-11-01
CO7131375A2 (es) 2014-12-01
EA030383B9 (ru) 2018-12-28
MX2014013571A (es) 2014-12-08
CN106983751A (zh) 2017-07-28
CA2872906A1 (en) 2013-11-14
MY181828A (en) 2021-01-08
PE20142301A1 (es) 2014-12-19
CU20140129A7 (es) 2015-02-26
PH12014502496A1 (en) 2015-01-12
HRP20160796T1 (hr) 2016-08-12
JO3290B1 (ar) 2018-09-16
EP3045456A1 (de) 2016-07-20
CL2014003031A1 (es) 2015-03-06
KR20150016548A (ko) 2015-02-12
US9949977B2 (en) 2018-04-24
BR112014028086B1 (pt) 2021-09-21
RS54901B1 (sr) 2016-10-31
BR112014028086A2 (pt) 2020-12-01
EA030383B1 (ru) 2018-07-31
IL253950B (en) 2019-07-31
TW201406744A (zh) 2014-02-16
DOP2014000255A (es) 2015-02-27
SI3045456T1 (en) 2018-03-30
AU2013258223B2 (en) 2017-11-09
US20170020875A1 (en) 2017-01-26
CN104395310B (zh) 2017-05-03
PT3045456T (pt) 2018-01-30
RS56784B1 (sr) 2018-04-30
EA031222B1 (ru) 2018-12-28
LT3045456T (lt) 2018-02-12
ES2581537T3 (es) 2016-09-06
SG10202003175QA (en) 2020-05-28
ZA201408146B (en) 2017-01-25
HUE035462T2 (en) 2018-05-02
CY1119840T1 (el) 2018-06-27
SA113340533B1 (ar) 2015-10-12
PT2847190T (pt) 2016-07-14
UY34797A (es) 2013-11-29
HK1202873A1 (en) 2015-10-09
AR090994A1 (es) 2014-12-30
US20150148340A1 (en) 2015-05-28
US20180256576A1 (en) 2018-09-13
NO3045456T3 (nl) 2018-03-24
AU2013258223A1 (en) 2014-11-27
US9949978B2 (en) 2018-04-24
ECSP14026138A (es) 2015-12-31
NZ701700A (en) 2016-09-30
PL3045456T3 (pl) 2018-03-30
DK2847190T3 (en) 2016-07-25
TN2014000470A1 (en) 2016-03-30
EP3045456B1 (de) 2017-10-25
PL2847190T3 (pl) 2016-12-30
TWI635085B (zh) 2018-09-11
AP2014008096A0 (en) 2014-12-31
CR20140513A (es) 2014-12-02
JP2015516000A (ja) 2015-06-04
EP2847190B1 (de) 2016-04-06

Similar Documents

Publication Publication Date Title
AU2017265047B2 (en) Bicyclically substituted uracils and the use thereof
WO2015067651A1 (de) Substituierte uracile als chymase inhibitoren
EP3066098A1 (de) Substituierte uracile und ihre verwendung
EP3066095A1 (de) Substituierte 1,2,4-triazin-3,5-dione und ihre verwendung als chymase hemmern

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13720407

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2013720407

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 235438

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2015510754

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2872906

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: P1202/2014

Country of ref document: AE

Ref document number: 001986-2014

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 2014003031

Country of ref document: CL

Ref document number: 14399945

Country of ref document: US

Ref document number: 14246970

Country of ref document: CO

Ref document number: CR2014-000513

Country of ref document: CR

Ref document number: MX/A/2014/013571

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 122021012427

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2013258223

Country of ref document: AU

Date of ref document: 20130503

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147034155

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201492040

Country of ref document: EA

Ref document number: IDP00201407666

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: A201413167

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: P-2016/0510

Country of ref document: RS

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014028086

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112014028086

Country of ref document: BR

Free format text: REAPRESENTE O RELATORIO DESCRITIVO COM A PAGINA 125 DEVIDAMENTE NUMERADA.

ENP Entry into the national phase

Ref document number: 112014028086

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141110